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Abstract 
Intimate partner violence among HIV-infected pregnant women initiating antiretroviral 
therapy in South Africa 
Background 
Intimate Partner Violence (IPV) is recognized globally as a major public health concern linked to 
numerous adverse physical, mental, sexual and reproductive health outcomes. IPV is associated 
with both pregnancy and HIV-infection independently, but there are few data on IPV in 
populations of HIV-infected pregnant women. We examined the prevalence and predicators of 
IPV among pregnant women initiating lifelong antiretroviral therapy (ART) in a large primary 
care clinic in Cape Town, South Africa. 
Methods 
Consecutive pregnant women seeking antenatal care in Gugulethu, Cape Town were recruited 
into the MCH-ART study examining service models for postpartum ART care. IPV, depression, 
alcohol and drug use, and emotional distress were assessed using the 13-item WHO Violence 
Against Women questionnaire, the Edinburgh Postnatal Depression Scale (EPDS), alcohol and 
drug use disorders identification test (AUDIT/DUDIT) and the Kessler-10 (K-10) scale, 
respectively. Questionnaires were administered privately by trained interviewers. Women 
identified with specific IPV or mental health concerns were referred to appropriate services. 
Logistic regression was used to examine factors independently associated with experiences of 
IPV after adjusting for age and socioeconomic status. 
Results 
From April 2013-May 2014, 623 women were enrolled (median age, 28 years):97% reported 
being in a relationship, 38% were married and/or cohabiting and 70% reported not having 
discussed or agreed on pregnancy intentions prior to conception. Overall, 21%(n=132) reported 
experiencing ≥1 act of IPV in the past 12 months, including emotional violence(15%), physical 
violence(15%) and sexual violence(2%). Of those reporting any IPV, 48% reported experiencing 
multiple types. Emotional and physical violence were most prevalent among women 18-24 years 
old, while sexual violence was most commonly reported among women 25-29 years old. Women 
who reported not discussing or disagreeing on pregnancy intentions with their partners prior to 
conception were significantly more likely to experience violence(p=0.030), and women who 
experienced IPV reported higher levels of substance abuse, depression and emotional 
distress(p<0.001 for all associations). 
Discussion 
These data demonstrate high levels of IPV in this population. While the potential impact of HIV- 
infection, pregnancy and pregnancy intention on the risk of IPV and related factors require 
further research, IPV-related screening and support services should be considered as part of the 
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Intimate partner violence (IPV) is generally accepted as a major public health concern, with serious 
effects on victims’ physical, mental, sexual and reproductive health. Rates of IPV are found to be higher 
in low- and middle-income countries (LMICs), and the regional prevalence of IPV in Africa is among the 
highest globally. Research has shown high levels of IPV among South African populations. This study 
will be conducted among a vulnerable population of pregnant HIV-infected women accessing health 
services in Gugulethu, Cape Town. We aim to determine the prevalence of IPV (overall, physical, 
emotional and sexual violence), identify risk factors associated with women’s experiences of IPV and 
explore potential screening methods to identify women experiencing IPV. A secondary data analysis will 
be conducted using data from a Maternal and Child Health Antiretroviral Treatment (MCH-ART) study, 
which is currently underway and aims to evaluate the efficacy of a maternal health-focused antiretroviral 




IPV has been shown to increase one’s risk of HIV infection, and the 2009-2011 UNAIDS Outcome 
Framework identified ending violence against women and girls as a priority in fighting the global 
HIV/AIDS epidemic. In South Africa, there is evidence to support IPV as a driver of the HIV epidemic. 
While the effects of pregnancy on the risk of IPV are unclear, research suggests that in LMIC settings 
pregnancy increases women’s risk of experiencing IPV. Besides an increased risk of HIV infection, a 
number of negative health outcomes for women experiencing IPV have been established, including 
depression, emotional distress, alcohol and drug use, preterm labor, delivering low birth weight babies, 
miscarriage and femicide (death). 
 
 
IPV is a potentially important factor in understanding the HIV epidemic in South Africa and in delivering 
women the most effective care. Pregnant HIV-positive women experiencing IPV are an extremely 
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vulnerable group and antiretroviral treatment programs are a potentially important point of access for IPV 
screening and prevention practices.  The prevalence and effects of IPV among pregnant women and 
among HIV-infected women have been looked at separately, but no known research exists in pregnant 
and HIV- infected populations in South Africa. This study aims to address that gap in knowledge. 
 
 
II. Key issues in IPV as a public health concern 
 
Gender Based Violence (GBV) and more specifically IPV is now recognized as a major public health 
concern worldwide [1–4]. The World Health Organization (WHO) estimates that 30% of ever-partnered 
women globally have experienced physical and/or sexual IPV [3], and findings from a multi-country 
study in sites across the world found that between 15% (Japan) and 71% (Ethiopia province) of women 
reported experiencing physical and/or sexual IPV in their lifetime [5]. 
 
 
By region, the prevalence of IPV in Africa is among the highest, estimated at 36.6% [3]. A systematic 
review of 13 studies of IPV in Africa found prevalence estimates to range from 2-57%, with a meta- 
analysis prevalence of 15% [6]. A South African population based survey conducted in 1998 found 13% 
of women reported lifetime experiences of physical IPV, and 6% reported violence in the past year [7]. 
 
 
IPV is associated with a number of adverse physical, mental, sexual and reproductive health outcomes, 
including: bruises; welts; fractures; head, back and neck injuries; chronic health problems; stress-induced 
physiological issues; post-traumatic stress disorder; depression; emotional distress; drug and alcohol 
abuse; unsafe sexual behaviors; increased risk of HIV infection; unintended pregnancies; and adverse 
pregnancy events such as preterm labor, delivering low birth weight babies and miscarriage [1–5, 8]. In 
2009, the rate of women killed by intimate partners in South Africa was 5.6/100,000, more than double 
that of the United States[9]. 
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IPV is considered a critical influencing agent of the HIV epidemic in sub-Saharan Africa [10, 11]. Higher 
rates of IPV are seen among HIV-infected populations, and the WHO estimates that women who are 
HIV-positive have 1.52 greater odds of experiencing IPV compared to women who are not HIV-positive 
[1, 3]. Researchers have argued that this is likely a result of gender inequalities and relationship inequities 
that decrease a woman’s power and decision-making ability in a relationship, and increase risk-taking 
behaviors [1–3, 10–13]. 
 
 
Existing data on the effects of pregnancy on the risk of IPV are not conclusive, however there is evidence 
to suggest that in a LMIC setting such as South Africa, the risk of experiencing IPV increases during 
pregnancy [8]. A recent study found that among a population of women attending a public clinic in 
Durban, South Africa, 21% reported experiencing IPV in their recent pregnancy, and 25% reported some 
form of IPV in the first four months postpartum [14]. In another study, 30% of women attending an 




The MCH-ART study aims to evaluate two models of antiretroviral therapy (ART) delivery; the standard 
practice of care currently offered in South Africa, and a maternal health-centered method of ART delivery 
during prenatal and postpartum periods. The goal is to maximize ART retention and adherence by 
optimizing treatment for pregnant women and new mothers. Research has shown that HIV-infected 
women are faced with a unique set of challenges surrounding ART adherence in pregnancy and during the 
postpartum period in particular[16]. Optimizing ART treatment to maximize retention and adherence will 
have positive health outcomes for HIV-infected women and their exposed infants[17]. Women’s 
experiences of IPV play a potentially crucial role in achieving this goal. Research has linked IPV in HIV- 
infected populations to a decrease in ART adherence [18]. Similarly, emotional distress, a common 
comorbidity seen among women experiencing IPV [19], has been found to make women receiving HIV 




III. Study objectives 
 
The role of IPV in this population represents a potential barrier to optimizing ART treatment [18]. Further 
research is needed to evaluate the burden of IPV in this population, understand the factors associated with 
IPV and evaluate the potential benefits of including screening, support and prevention strategies in the 
package of care for ART in pregnancy. In order to address these gaps in knowledge, this study aims to 
fulfill a number of objectives: 
 
 
Primary objective: Determine the prevalence of IPV (overall, physical, emotional and sexual) in the past 
12 months among pregnant HIV-infected women in Gugulethu, Cape Town. 
Secondary objectives: 
 
1) Identify risk factors associated with women’s experience of violence in the past 12 months. 
 
2) Examine the relationship between participants’ time of first HIV-positive diagnosis and their risk 
of experiencing IPV in the past 12 months. 
3) Examine the relationship between participants’ pregnancy intentions prior to conception and their 








Research will be conducted at the Gugulethu Community Health Centre (CHC) in Cape Town. 
Researchers have been involved with treatment and service delivery at the facility since 2003 and have 
previously had success carrying out research in conjunction with the provincial government. HIV 
prevalence in 2011 was 31% and 24% among women attending the Gugulethu antenatal clinic and those 
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in the surrounding district, respectively. The Gugulethu Maternal and Obstetrics Unit (MOU) is 
responsible for providing primary antenatal care services. In 2010, an estimated 4,900 women sought 





The MCH-ART study, a multi-phase study design, will provide the data for this study. 
 
Phase 1 is a cross-sectional evaluation of consecutive HIV-infected pregnant women presenting for care 
at the MOU (their first antenatal visit). 
Phase 2 is an observational cohort study of women from Phase 1 who were eligible for lifelong 
antiretroviral treatment initiation, according to local guidelines at the time, upon presenting for antenatal 
care at the MOU. This phase will follow women from their second antenatal visit through their first 
postpartum visit (within one week of delivery). 
 
 
Analysis for this study will be conducted as an observational cross-sectional study, with data collected 
during participants’ first visit of Phase 2, i.e. their second antenatal visit. Some demographic data 




Characteristics of the study population 
 
Phase 1 participants will be consenting pregnant HIV-infected women presenting for antenatal care at the 
Gugulethu MOU. Phase 2 participants will be those phase 1 participants who are eligible for ART 







• Age 18 years or older 
 
• Documented HIV-infection according to two finger-prick rapid tests using different test types (per 
routine protocol in this setting) or documentation of HIV status for those women self-reporting HIV 
diagnosis 
• Confirmed pregnancy according to urine pregnancy test, ultrasound or clinical assessment 
 
• Has not initiated triple-drug antiretroviral therapy or AZT for PMTCT during the current pregnancy 
 
• Able to provide informed consent for research 
Phase 2: Phase 1 participants who are ART-eligible 
• Consented and participated in Phase 1 
 
• Documented ART eligibility based on current local guidelines 
 
• Started or scheduled to start ART at Gugulethu MOU in the current pregnancy (women started on 
AZT for PMTCT during the current pregnancy are eligible) 
• Women who were previously receiving lifelong ART must have not used ART for at least six 
months. 






Individuals meeting any of the following criteria will be excluded: 
 
• Not currently pregnant 
 
• Intention to relocate out of Cape Town permanently during the study period (Phase 2 only) 
 
• Any medical, psychiatric or social condition which in the opinion of the investigators would affect the 
ability to consent and/or participate in the study (all phases), including: 
o Refusal to take ART 
 




Recruitment and enrolment 
 
All women presenting at the MOU for their first antenatal visit during this pregnancy with documented 
HIV infection will be told about the study by MOU staff. If a potential participant shows interest in 
enrolling MOU staff will either (a) introduce her to a study staff member based at the MOU or (b) ask the 
potential participant if a member of the study staff can approach her directly. Study staff will provide 
potential participants with basic information regarding the study. If women express interest in enrolling in 
the study, study staff will administer a screening process to ensure potential participants meet the 
inclusion/exclusion criteria previously outlined. Those women determined to be eligible will complete an 
informed consent form, which includes consent to have medical data abstracted from their patient records 
and to be approached at a later date regarding future research. 
 
 
At the second antenatal visit, Phase 1 participants determined to be ART-eligible and fulfill the inclusion 
requirements outlined above will be approached by study staff to participate in Phase 2. If a participant 
agrees she will complete a second written informed consent form (Appendix P1) and be enrolled in Phase 
2. Women who participate in Phase 1 but are ineligible or refuse to participate in further phases will have 
information abstracted from their routine clinical records. This is outlined in the Informed Consent form 
provided to participants enrolling in both Phases 1 and 2.  
 
 
Throughout the study, trained staff members will ensure that participants are aware that they are free to 
refuse and/or withdraw from the study at any point. Additionally, all participants will be informed that all 
study procedures are completely separate from standard antenatal and postnatal care offered at the facility, 
and that their decision to refuse and/or withdraw from the study will in no way prevent them from 
accessing any health care services offered at the MOU or other public sector health centers. 
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Research procedures and data collection methods 
 
Study procedures will include data collected from routine antenatal PMTCT and ART services offered at 
the Gugulethu MOU as a part of the local standard of care (presented below as ‘antenatal services at the 
Gugulethu MOU’), as well as additional study-specific data collected during the study measurement visits 
also outlined below. 
 
 
Antenatal services at the Gugulethu MOU (local standard of care services) 
 
• Routine blood testing (including ABO blood group, syphilis screening and haemoglobin) sent to the 
National Health Laboratory Services (NHLS) laboratory 
• Medical and obstetric history and examination performed by a nurse-midwife 
 
• Rapid HIV testing, with pre/post-testing counseling 
 
o Women who are HIV-infected receive counseling, undergo venesection for serum creatinine 
and CD4 enumeration, and then women not already taking ART are started on a triple-drug 
antiretroviral regimen immediately, per local PMTCT guidelines. 
o Breastfeeding counseling begins at the first antenatal care visit, with all women encouraged 
to exclusively breastfeed for 6 months. Follow-up counseling is provided throughout the 
antenatal period. 
o Pregnant women receiving ART at the MOU return 1-2 monthly for follow-up visits and 
medication refills until delivery. Women already receiving ART elsewhere, continue their 
care at their current ART clinic. 
 
 
Study measurement visits 
 
Phase 1: After recruitment and informed consent are completed at the first antenatal care visit, women 
will complete a brief (approximately 20 minutes) study measurement visit in which (a) a standardized 
questionnaire will be used to collect additional information and (b) 5mL of venous blood for batched viral 
10 
load testing will be collected. Questionnaires administered in this study measurement visit will collect 
information regarding: 
• Demographic characteristics, socioeconomic status, medical history, family planning, HIV testing
history and disclosure status, and previous antiretroviral exposure.
Phase 2: At the end of their second antenatal visit, participants who are ART-eligible according to current 
local guidelines and deemed to meet eligibility requirements will be invited to participate in Phase 2. 
Women who agree and complete the Informed Consent #2 form (Appendix P1) will undergo three study 
measurement visits. For the purposes of this analysis, only data from the first of these three visits (study 
visit 2) will be considered. This study measurement visit will last approximately 30-45 minutes. 
Participants will be administered a series of questionnaires and 5mL of venous blood will be collected for 
storage and batched viral load testing. Questionnaires administered in this study measurement visit will 
collect information regarding: 
• Demographics and medical history, IPV, mental health, substance use, pregnancy history and
intentions, social support, HIV status disclosure, and ART use and beliefs.
Referrals	  
If during any study visit a participant is found to have an unmet health need (medical, obstetric, 
reproductive, mental or otherwise) trained staff will urgently refer them to the appropriate health care 
services, either within the CHC or elsewhere, as necessary. Particularly: 
• Any participant reporting any form of gender-based violence or intimate partner violence will be
immediately referred to the local NGO providing support services (MOSAIC) and the South African
Police Services (per the Domestic Violence Act, No. 116 of 1998). Adequate focus will be given to
this issue in future follow-up.
11 	  
• Any participant found to be non-adherent to ART throughout the course of the study will be referred 
to the appropriate ART service, be it general adult or MCH-focused, through the Gugulethu MOU 






Laboratory specimens taken within the scope of this research project will amount to approximately 5 mL 
maternal venous blood per study measurement visit, for a maximum total of approximately 10 mL per 
participant. Each specimen will be collected in SST tubes and transported to the National Health 
Laboratory Services (NHLS) laboratory for storage. Maternal specimens will be used for HIV viral load 
testing (Abbott Molecular RealTime HIV-1 assay (Abbott Molecular, Illinois, USA)), done in batch 
testing. The remaining plasma will be divided into 3-4 aliquots of ±80µL each and stored for future 
research in Sarstedt screw cap tubes at -80oC. All specimen extraction, handling, processing and storing 






In addition to the measures described above, data abstraction from medical charts and files will be used to 
collect important data on participants’ antenatal and obstetric care and ART initiation and follow-up. 




Authorization for data abstraction will be obtained by (a) the participant (via informed consent), (b) the 
research oversight body of the Provincial Government of the Western Cape (PGWC), (c) the participating 
IRB/REC, and (d) the facility managers of each participating health facility. None of the data abstracted 




Before the beginning of the study, any staff member to have participant contact will undergo a multi-day 
training program specific to the MCH-ART study. Training will cover study purpose and objectives, 
study design and methodology, conduct of study assessments, tracking of participants, data collection, 
participant enrolment procedures, staff responsibility, ethical guidelines for research including human 
participation, issues of confidentiality, participants’ rights and informed consent procedures. 
 
 
Study staff training will be hands-on and include an introduction to the forms and data collection 
procedures and techniques to be used throughout the study. Mock interviews will be used to allow staff to 
practice delivering information to participants and role-play as both staff members and as participants. 
Training will also prepare staff to handle crisis situations, including reports of IPV which may be 
disclosed during participant interviews. Procedures to handle such situations and make appropriate 
referrals will be established at the study site and outlined in study standard operating procedures (SOPs). 
Additional training days will be scheduled for all staff members throughout the course of the study to 




Data safety and monitoring 
 
Data will be managed at the MOU using standard operating procedures that have been established and 
successful in multiple previous studies. Any data collected on paper will be entered into a Microsoft 
Access database which has been specially designed and will be maintained in a UCT server, protected by 
a firewall and backed-up nightly. The database, which a senior data manager will design and maintain, 
will be password protected per standard password safety procedures. The data manager will also create 
the data dictionary, handle queries, and ensure quality control whilst supervising the data enterer. Data 
quality control will be achieved through a robust database design and set-up, “front-end” data checks and 
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real-time queries. All data queries will be logged; references to source forms and separate program files will 
be used for data edits. All participant records will use anonymous participant identification numbers and no 
names or identifiers will be recorded. Any data disseminated to personal computers for the purposes of 





All data analysis will be done in Stata 12 (Stata Corporation, College Station, Texas). All analyses will be 
conducted under the supervision of Professor Landon Myer, MCH-ART Principal Investigator, with the 
additional advisement of the study statistician as needed. 
 
 
The analysis population will include all Phase 1 participants found to be ART-eligible who presented and 
consented to Phase 2 participation. To fulfill our primary objective, the prevalence of overall, physical, 
emotional and sexual IPV will be calculated. 
 
 
To address secondary objectives number 1, descriptive statistics will be used on all demographic, 
relationship and behavioral characteristics of interest. Ranksum tests, 2-sample t-tests, χ2 and Fisher’s exact 
tests will be used to determine if these characteristics are statistically significantly different among women 
who reported IPV in the past 12 months compared to those who did not. Logistic regression will be used to 
evaluate factors associated with experiences of IPV, adjusted for age and socioeconomic status. Models 
including relationship characteristics will be built separately from those including behavioral characteristics 
in order to avoid confounding and inducing associations through back-door variable relationships. In order 
to address secondary objective numbers 2 and 3, logistic regression models stratified by (a) time of first 
HIV-positive diagnosis and (b) pregnancy intention prior to conception will be run. 








This study will not require any further budget allotment. All costs associated with data collection, 




IV. Ethical considerations 
 
The MCH-ART study was granted ethics approval from both the University of Cape Town Faculty of 
Health Services Research Ethics Committee (UCT-HREC) and the Columbia University Medical Center 
Institutional Review Board (CUMC-IRB). No additional data will be collected from participants for the 
purposes of this secondary analysis. However, as with any research involving human subjects, certain 




Description of risks and benefits 
 
Possible risks to participants: 
 
The potential risks to participants involved in this study include: 
 
• The post-traumatic stress associated with reporting and recalling a history of IPV. As previously 
mentioned, interviewers and study staff will be trained in dealing with the disclosure of such 
traumatic events, and will be ready and able to make referrals to appropriate services as necessary. 
• Similarly, other questionnaires regarding mental health, substance use, HIV status disclosure and 
treatment adherence may hold risk of increasing participants’ emotional distress. As above, study 
staff will be trained in how to deal with these disclosures, and refer participants to the relevant 
services as needed. 
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• The potential complications associated with drawing blood and the collection of biological samples. 
 
• The potential loss of confidentiality resulting from study procedures, for example during data 
collection. As outlined below, an array of measures will be taken to prevent this from 
occurring. 
None of the above risks are specific to the study, and each of them may be encountered similarly during 
standard practice of care. All potential risks to participants will be clearly outlined in the informed 
consent forms given to participants, as will the study measures taken to prevent them. 
 
 
Possible benefits to participants: 
 
The main benefit of study participation is optimized ART treatment and care during pregnancy. By 
making ART treatment as effective as possible, the risk of mother-to-child HIV transmission (MTCT), 
which is particularly high among ART-eligible women, will decrease. Optimizing maternal care in this 
manner will have positive effects on the health of both mothers and babies, regardless of their HIV status. 
Additionally, for women experiencing IPV, psychosocial issues or harmful behavioral patterns, study 
participation will provide referrals for health and/or support services they may have been otherwise 
unaware of or unable to access. Therefore any risks associated with participation in this study are 
substantially less than the possible benefits. 
 
 
Possible benefits to the community: 
 
Learning more about the prevalence and predictors of IPV in this community will allow us to better 
understand the complexities of the HIV epidemic in South Africa, and thus more deeply understand the 
needs of women presenting for care. By identifying the optimal method for administering ART, HIV- 
infected women in this community and across South Africa will benefit from more efficacious care. The 
involvement of policy makers and other stakeholders involved in HIV care and maternal and child health 
will also aid in strengthening health services for HIV-infected pregnant women, thus increasing the 




Informed consent process 
 
Informed consent will be obtained before enrollment to any study phase by trained interviewers in 
participants’ home language (isiXhosa), using a standardized script. This script will clearly outline the 
purpose of the study all study procedures and the risks and benefits that participants in the study may 
encounter. At the time of obtaining informed consent, and throughout the study, interviewers and study 
staff will stress to participants that participation is voluntary and they are free to decline and/or withdraw 
from the study at any point without fear of losing access to standard care offered at public sector health 
centers or experiencing diminished quality of care. Each phase of the study requires its own informed 
consent, with specific regards to the nature of that phase. 
 
 
Informed consent #1: 
 
This will be given to all participants in Phase 1. The consent form will be completed by HIV-infected 
pregnant women presenting to the Gugulethu MOU for their first antenatal visit and determined to meet 
the eligibility requirements. This consent form provides information regarding study purpose and the 
following procedures: (a) completion of a demographic and behavioral questionnaire (b) obtaining a 
blood sample (c) permission to review medical charts and abstract information and (d) permission to 
contact the participant at a later date regarding future research. 
 
 
Informed consent #2: 
 
This consent form will be used for all Phase 1 participants who are deemed eligible for Phase 2 (i.e. ART- 
eligible and satisfy inclusion/exclusion criteria outlined above). This consent form introduces the purpose 
of the remaining two phases of this study (the observational cohort and randomized trial phases) as well 
as the specific procedures to be initiated in the remaining phases. A full version of this document can be 




Privacy and confidentiality 
 
A number of provisions will be made to ensure confidentiality is maintained, including: 
 
• All study staff will be trained specifically in confidentiality and subjects of patient protection 
 
• Per standard practice, all patient files and study-related documents will be kept in a locked cabinet at 
the study office either in Gugulethu or at UCT 
• Anonymous and random patient identification numbers will be used on all study materials. Names 
will only be recorded on informed consent documents, location tracing materials and a study 
identification key. All of these materials will remain locked in separate locations from the 
aforementioned study materials, accessible only by the project coordinator and local PI 
 
• All electronic data will be stored in password-protected and encrypted files. Data storage at UCT will 
be restricted to a firewall-protected SQL server 
Efforts will be made to ensure confidentiality at all times, however should staff discover that a participant 
poses a possible threat to themselves or others, including but not limited to issues of child abuse or 
neglect, measures to notify the appropriate authorities will be taken. Participants will be made aware of 
this exception in all informed consent documents presented to them. 
 
 
Reimbursement for participation 
 
Participants will be compensated for their time in the form of R20 in cash to cover transportation costs to 
attend their next scheduled study visit, R80 in grocery vouchers and up to R50 in refreshments, as well as 
a small gift at their first and last post-partum visits. 
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V. Dissemination strategy 
 
Upon completion of analysis and reporting, student researcher will discuss publication options with both 
supervisors. The goal will be to publish findings in a peer-reviewed journal in order to add to the limited 
body of existing research focusing on IPV among pregnant and HIV-positive women in LMIC settings. 
Publication and presentation of the results of this study will be discussed and agreed upon by all involved 
parties. These decisions, along with those regarding the nature of the data to be presented, will be made 
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This literature review aims to: 
• Describe the epidemiology of IPV globally, regionally and locally, and among pregnant women
and HIV-infected women individually
• Contextualize the theoretical basis for the proposed analysis
• Review existing literature on the effects of IPV on ART adherence
• Identify any gaps in knowledge that the proposed analysis will address
II. Methodological approach to literature review
An initial search of PubMed and Google Scholar was conducted to find relevant literature. Search terms
used were “Intimate Partner Violence AND HIV AND pregnancy”, “Intimate Partner Violence AND
Africa”, “Intimate Partner Violence AND South Africa”, “Intimate Partner Violence AND HIV”,
“Intimate Partner Violence AND HIV AND Africa”, “Intimate Partner Violence AND HIV AND South
Africa”, “Intimate Partner Violence AND pregnancy”, “Intimate Partner Violence AND pregnancy AND
Africa”, “Intimate Partner Violence AND pregnancy AND South Africa”, “Intimate Partner Violence
AND pregnancy intention”, “Intimate Partner Violence AND unintended pregnancy”, “Intimate Partner
Violence AND ART”, “Intimate Partner Violence AND ART AND adherence”, “Intimate Partner
Violence AND alcohol AND South Africa”, “Intimate Partner Violence AND drugs AND South Africa”,
“Intimate Partner Violence AND substance use AND South Africa”, “Intimate Partner Violence AND
depression AND South Africa”, and “Intimate Partner Violence AND emotional distress AND South





What is Intimate Partner Violence (IPV)? 
 
 
Intimate Partner Violence (IPV) is defined as any “behavior within an intimate relationship (current or 
former spouses or partners) that causes physical, sexual and psychological harm, including acts of 
physical aggression, sexual coercion, psychological harm, and controlling behaviors.” [1] 
 
 
The World Health Organization estimates that between 15% and 71% of women around the world 
experience at least one act of physical and/or sexual intimate partner violence at some point in their lives 
[1–4]. IPV has been identified as a major global public health concern, with serious consequences for 
victims’ physical, mental, sexual and reproductive health [5]. 
 
 
The etiology of IPV: An ecological model within the context of Public Health 
 
 
Intimate partner violence is a complex phenomenon that can be difficult to explain and even more so to 
understand. In their 2010 report, the World Health Organization outlined a number of perspectives 
through which IPV can be viewed and understood [1]. One such theoretical foundation of understanding, 
the ecological model, categorizes factors associated with IPV into four levels [1], as illustrated in Figure 1. 
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This paper uses the ecological model to understand the etiology of IPV by understanding associated 
factors within the context of four categories: 
• The individual level includes biological factors, personal history, and any other characteristics 
that may increase a person’s probability of falling victim to IPV. 
• Relationship level factors occur between intimate partners and include things such as duration of 
relationship, marital status, and partner cohabitation. 
• The community level is the context within which social relationships thrive: school, work, 
religious institutions, etc. 
• The societal level includes macro-level factors that influence IPV, such as legislation protecting 
victims and/or prosecuting perpetrators of IPV, cultural belief systems, societal norms, and 
economic, social or political policies which create or sustain gaps or inequalities that may affect 
one’s risk of IPV. 
 
 
The ecological models presents a comprehensive approach to understanding IPV, capable of accounting 
for factors from different levels, spaces and times, and considering how they affect a person’s risk of 
experiencing IPV is various ways [1]. 
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The Public Health Perspective is a “science-driven, population-based, interdisciplinary, intersectoral 
approach based on the ecological model which emphasizes primary prevention.” This approach offers the 
maximum benefit for the greatest amount of people, and has the ability to understand IPV in a complex 
manner, fitting of the complexities inherent in the phenomenon itself. This approach also allows one to 




IV. Epidemiology of IPV 
 
IPV global burden of disease 
 
 
It is estimated that 30% of ever-partnered women globally have experienced physical and/or sexual 
violence at the hands of an intimate partner [3]. In 2006, the WHO published findings from the Multi- 
Country Study on Women’s Health and Domestic Violence, which interviewed over 24,000 women, aged 
15-49 in 15 sites across 10 countries [4]. The standardized household survey methods found that among 
ever-partnered women between 15% (Japan) and 71% (Ethiopia Province) reported a lifetime history of 
sexual or physical violence, or both- with most prevalence estimates falling between 29% and 62%. 
Between 4% and 54% reported physical or sexual IPV or both in the past 12 months, with most estimates 
falling between 15% and 35%. 
 
 
The majority of women who reported violence in the past year experienced multiple acts of violence in 
that time. Violence often coexisted, and in most sites, between 30% and 56% of women who reported any 
violence had experienced both physical and sexual violence. Between 21% and 90% of ever-partnered 
women experienced at least one act of controlling behavior by their partners, and women who reported 
physical and/or sexual violence were more likely to have these controlling constraints placed upon them 
at the hands of their partners, across all sites[4]. 
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Findings suggested that IPV begins early in life, is often part of an ongoing pattern of violence and severe 
[4]. Consequences of IPV can be extreme, with an estimated 38% of all murders of women occurring 
globally being perpetrated by intimate partners [3]. 
 
 
IPV in Africa 
 
 
Overall, rates of IPV are found to be higher in LMIC settings [6]. According to the WHO, the African 
region has one of the highest IPV prevalence estimates in the world, at 36.6%[3]. Results from a multi- 
country study consistently showed some of the highest estimates of IPV coming from African nations [4], 
suggesting that IPV is a major issue throughout the region. In a survey conducted across eight countries in 
southern Africa, 18% of women reported experiencing IPV in the past year [7], and a study of women in 
steady relationships in Rwanda reported a 21% prevalence of past physical violence [8]. 
 
 
IPV in South Africa 
 
 
Research has suggested that IPV may be more pervasive in settings with high rates of violence and gender 
power inequity [4], and in societies in which the status of women is in a state of transition [1]. This 
backdrop supporting pervasive patterns of violence may be very relevant to a number of South African 




A nationally representative survey conducted in South Africa reported 13% of women had experienced 
lifetime physical IPV. Violence in the past year was reported by 6% of participants, 43% of whom 
reported needing medical attention as a result of those experiences of violence [10]. These figures are 
lower than most other estimates of IPV in South Africa. It is worth noting that under-reporting is common 
7 
in this field, and another study in one South African province estimated a 27% prevalence of physical IPV 
among ever-partnered women in a sub-set of an SADHS enumeration area which was estimated to have a 
9% prevalence of physical IPV in this survey study [10]. 
A study sampling from antenatal clinics outside of Cape Town used a 4-point frequency scale to estimate 
a lifetime prevalence of 41%, 37% and 12% for emotional, physical and sexual IPV respectively [6]. In a 
cross-sectional study conducted among rural women, 54% reported some form of lifetime IPV (physical, 
sexual or emotional) [11]. An analysis of interviews conducted with women in an antenatal clinic in 
Soweto produced similar findings, with 56% of participants reporting a lifetime history of physical or 
sexual IPV [12, 13]. Of these women, 43% reported more than one incident of violence in their lifetime, 
and only 22% of the total sample reported experiencing no IPV in their lifetime [13]. 
According to a WHO report, 42% of 13-23 year-old females in South Africa reported a history of physical 
dating violence [2], further supporting the notion that violence often begins young and remains pervasive 
throughout women’s lifetimes. High reported prevalence estimates of IPV by women are further 
supported by studies among men, in which many admit to IPV perpetration. In a study of men in Cape 
Town, 42% admitted to perpetrating physical violence against a partner in the past 10 years. Sexual 
violence in the past 10 years was reported by 15% and emotional abuse reported by 42% [14, 15]. Most 
extremely, the 2009 rate of intimate partner femicide in South Africa was 5.6/100,000, more than double 
that of the United States [16]. 
Risk factors associated with IPV 
The WHO has identified a number of risk factors for experiencing intimate partner violence [1, 3]. These 
are presented in Table 1, adapted from a 2010 WHO report [1]. It should be noted that there remains 
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Table LR1: Risk Factors for Experiencing IPV 
 
INDIVIDUAL LEVEL 
Demographics • Young age 
• Low SES 
• Low education 
• Pregnant 
Exposure to Child Maltreatment • Intra-parental violence 
• Sexual abuse 
Mental Disorder • Depression 
Substance Use • Harmful use of alcohol 
• Illicit drug use 
Attitudes and Experiences of violence • Acceptance of violence 
• Exposure to prior violence/victimization 
RELATIONSHIP LEVEL 
Relationship Factors • Marital status 
• Educational disparity 
• Number of children 
Relationship Quality • Marital dissatisfaction/discord 
COMMUNITY LEVEL 
Gender Beliefs • Acceptance of traditional gender roles 
Neighborhood Characteristics • High rates of poverty 
• High rates of unemployment 
• High rates of female illiteracy 
• Acceptance of violence 
• Low proportion of women with high levels 
of autonomy 
• Low proportion of women with higher 
education 
SOCIETAL LEVEL 
Legislation • Governmental divorce regulations 
• Lack of legislation on IPV 
• Protective marriage laws 
Gender Norms • Traditional gender and social norms that 
support violence 
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IPV and health outcomes 
 
 
Battered women experience more negative physical, mental, sexual and reproductive health outcomes 
than non-battered women [5]. In general, these outcomes can manifest themselves in two ways: direct 
outcomes (injury, disability, death, etc.) and indirect outcomes (stress-induced physiological changes, 
chronic health problems, etc.) [1–3]. Table 2 presents a number of direct and indirect health outcomes that 
have been found to be associated with experiences of IPV. 
 
 
Table LR2: Health outcomes associated with experiences of IPV 
 
	   OUTCOMES 
Physical health [1–3, 5] Bruises, welts, lacerations, abrasions, abdominal and thoracic 
injuries, fractures, broken bones/teeth, sight and hearing 
damage, head, back and neck injuries, stress-related conditions 
(Irritable bowel syndrome, gastrointestinal symptoms, 
fibromyalgia, chronic pain syndroms, exacerbation of asthma), 
disability, death 
Mental Health [1–3, 5] Depression, PTSD, anxiety, phobias, emotional distress, 
suicidal thoughts, eating and sleep disorders, physical 
inactivity, poor self-esteem, smoking, self-harm and unsafe 
sexual behaviour, alcohol and drug abuse 
Sexual/Reproductive 
Health [1–3, 5, 18] 
Higher rates of unintended pregnancy, abortions, unsafe 
abortions, STIs including HIV, adverse pregnancy events 
(miscarriage, pre-term births, stillbirths), pregnancy 
complications, pelvic inflammatory disease, UTIs and sexual 




IPV and causal pathways 
 
 
Causal pathways between IPV and health outcomes can often be complex and difficult to make sense of, 
specifically indirect pathways [3]. The figure below, adapted from a 2013 WHO report, presents three 
ways in which adverse health outcomes can result from experiences of IPV [3]. It should be noted that the 
proposed analysis is not a thorough investigation of all causal pathways. 
10 	  
 







V. IPV among pregnant women 
 
 
There remains discord regarding the effects of pregnancy on the risk of IPV. A WHO multi-country study 
estimated the prevalence of IPV during pregnancy to be between 1% and 28% in sites around the world, 






























   
   
 






























Research in Zimbabwe suggests that pregnancy could be protective against IPV due to the value placed 
on an unborn child’s life, or that the risk could fluctuate throughout different stages of pregnancy [19, 20]. 
However it has generally been found that the risk of experiencing violence increases during pregnancy for 
women in LMIC settings [6]. 
 
 
Health outcomes associated with IPV during pregnancy 
 
Women who experience IPV, especially those in LMICs, also experience a lack of fertility control due to 
fear and the threat of violence, which can lead to unintended pregnancy [21]. This can have adverse 
health effects for both the mother experiencing violence and the child being born into an abusive cycle 
household [21, 22]. Research has shown that women experiencing violence during pregnancy report high 
levels of anxiety and depression, which can often lead to substance use [21, 22]. Furthermore, IPV in 
pregnancy has been shown to be associated with unintended pregnancy, induced abortion, late entry to 
prenatal care, premature labor and delivery, low birth weight or small for gestational age babies, adverse 
effects on postpartum breastfeeding, fetal injury, miscarriage, stillbirth, fetal death [2, 3, 21, 22]. 
Children of IPV victims are less likely to be immunized, have higher rates of diarrheal disease and an 




IPV among pregnant women in Africa 
 
 
Research has shown high estimates of IPV prevalence during pregnancy in the region, including 13.5% in 
Uganda [2]. Demographic and Health survey data from a number of African countries reported a 
prevalence of physical and/or sexual violence in the past 12 months of 31% in Kenya, 20% in Malawi, 
22% in Rwanda, 28% in Zambia and 30% in Zimbabwe [23]. A systematic review of 13 studies of IPV 
during pregnancy in Africa found prevalence ranges of 2% to 57%, and reported a meta-analysis 
prevalence of 15.23%[24]. 
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A 2012 qualitative study of IPV during pregnancy in Zimbabwe found that often violence during 
pregnancy was used as a means of maintaining gender power imbalances and controlling women. 
Coercive sexual practices were common, and threats of violence or the use of overt violence was used to 
control female sexuality. Coupled with cultural norms that undermined women’s agency over their own 
sexuality, and increased financial reliance on men, this constructed a very powerful force of control [20]. 
 
 
A cross-sectional study found all gender inequality factors to be associated with both physical and sexual 
IPV in Zimbabwe [25]. Both forms of IPV were associated with a younger age at first pregnancy, and 
independent decision-making regarding pregnancy. Findings showed that pregnancy increased a woman’s 
risk of IPV if she had decided to become pregnant alone, but that it was protective against IPV if the male 
partner had intended it [25]. Results also suggested that IPV during pregnancy is not an isolated event, 
but part of a larger pattern of violence. Of women reporting IPV, 10% experienced more than 6 events of 




IPV among pregnant women in South Africa 
 
 
In a nationally representative survey study, 4% of ever partnered women reported physical violence 
during pregnancy [10], much lower than estimates gathered from a number of other clinic-based studies. 
Among pregnant women sampled in a clinic outside of Cape Town 32% and 25% reported emotional and 
physical IPV respectively in the past 12 months [6]. While 21% of women attending an antenatal clinic in 
Durban reported IPV in pregnancy [26]. In a similar study from Soweto, 30% of women sampled reported 
experiences physical or sexual IPV in the past year, and 22% of the overall sample reported experiencing 
multiple incidents of violence [13]. 
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Health outcomes associated with IPV among pregnant women in South Africa 
A study conducted outside of Cape Town found that women with a past-year history of physical IPV 
were significantly more likely to deliver low birth weight babies compared to those who did not 
report experiences of physical IPV in the preceding 12 months [6], while pregnant women in Durban 
reporting physical IPV had a 1.48 times great odds of emotional distress for each act of physical 
violence experienced. The odds of emotional distressed increased by 1.53 and 2.99 for psychological 
and sexual violence during pregnancy, respectively [26]. Emotional distress has been linked to a 
number of adverse pregnancy outcomes, including preterm birth and postpartum depression [26]. 
In a study conducted in informal drinking establishments outside of Cape Town, 13% of women 
sampled reported pregnancy, 26% reported IPV, and experiences of IPV were associated with alcohol 
use among all women in the sample [27]. Alcohol use during pregnancy is associated with a number 
of negative health outcomes for babies, including Fetal Alcohol Syndrome (FAS), the rates of which 
in South Africa are the highest globally, particularly in the Western Cape [27]. 
VI. IPV among HIV-infected women
Women worldwide remain at an increased risk for both IPV and HIV-infection, both independently 
and concurrently, and evidence from a number of geographic locations and population groups support 
the association between experiences of violence and HIV-infection [28]. IPV and gender inequality 
are increasingly identified as a significant contributor to women’s HIV risk [12]. There is a significant 
overlap between HIV-infected women and battered women [29], and it is estimated that the odds of 
experiencing IPV among HIV+ women is 1.52 (1.03;2.23) times greater than that of HIV- women[3]. 
The WHO recognizes gender issues as critically influencing the HIV epidemic both globally and in sub- 
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Saharan Africa [30]. In southern Africa, it is estimated that 1 in 3 people are involved in the cycle of 
intersections between GBV and HIV [7]. A study in Rwanda found that reports of IPV were more than 
double in HIV-infected women compared to those who were not infected (OR=2.38 [1.59;3.57])[31]. 
And in Zimbabwe, IPV is considered a structural driver of HIV, both of which, authors hypothesize, stem 
from gender inequalities [19]. 
Gender dynamics and links between IPV and HIV 
The association between IPV and HIV is compounded by gender, and the unequal associated power 
dynamics which exist within such structures [28]. While some of the association between HIV and IPV 
may a direct outcome, i.e. HIV infection through specific acts of sexual violence, this association can be 
better understood as an indirect effect of women in controlling and violent relationships [1–3]. Maman et 
al. describe four mechanisms of vulnerability which increase the risk of HIV acquisition in violent 
relationships: forced or coerced sex, fear of asking for condom use due to threat of violence, experiences 
of sexual violence and fear of abuse which contributes to concurrency of women’s sexual partners [32]. 
Qualitative research suggests that notions of masculinity that place value upon controlling women and 
male strength may translate into sexual risk taking, acts of violence against women and increased risk of 
HIV acquisition [3]. Women in relationships experiencing IPV often have low levels of power and agency 
over their own sexual decision-making. For example, a woman in a violent relationship may be unable to 
negotiate condom use for fear of violence, or struggle to discuss issues surrounding HIV status and 
protection with her partners [1–3]. There also exists notions of condimization being unnecessary with a 
woman who is “clean” which increases the likelihood of unprotected sex and hinders a woman’s ability to 
negotiate condom use [30]. Research has shown that men who perpetrate violence are more likely to be 
HIV-infected [3], putting disempowered women in violent relationships who are experiencing fear or 
difficulties negotiating safe sex practices at an even greater risk of HIV-infection. 
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IPV as a driver of HIV in South Africa 
 
 
The association between IPV and HIV has been shown in a number of South African settings. IPV was 
significantly associated with HIV seropositivity among women in Soweto (OR=1.48)[12]. Women with 
violent partners have also been shown to engage in more HIV risk behaviors [30] such as: having 
multiple partners and non-primary partners, transactional sex and substance abuse [12], not requesting 
condom use and not reporting condom use in the past six months [29] and having higher numbers of past 
year partners [33]. 
 
 
In a South African cross-sectional study, women who described their relationship as “not good” were less 
likely to request condom use [30]. Those who did request condoms were more likely to be educated, have 
multiple partners, and have a reported history of domestic violence and/or economic abuse. Research has 
hypothesized that due to the low status of women in many South African communities, a female’s social 
worth is proven by her ability to have and keep a man [30]. There are high stakes and benefits- especially 
economic stability- that come with being in a relationship [30]. Therefore, fear of abandonment, economic 
vulnerability and the stigma of being seen as ‘less than’ if unable to keep a man all contribute to women’s 
position of disempowerment within relationships, and therefore their reluctance to request condom use 
becomes a major obstacle for women [30]. 
 
 
Conversely women with better relationships were more likely to discuss HIV with their partner, however 
there was no indication that a history of IPV directly influenced discussions of HIV [30]. A later cohort 
study of young South African women reported that those with low relationship power equity at baseline 
and women who reported more than one experience of IPV at baseline were more likely to seroconvert 
during follow-up [9]. The population attributable fractions of HIV were 13.9% and 11.9% for women 
with low relationship power equity and women with a history of IPV, respectively [9].
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VII. IPV and ART: implications for adherence and retention
In a study conducted in the United States, IPV was found to have a statistically significant negative effect 
on ART adherence among HIV-infected women [34]. Treatment adherence is critical for suppressing 
HIV-infected patients’ viral loads, and poor adherence to ART can have a detrimental effect on disease 
management, causing patients to develop a resistance to medication and eventually result in treatment 
failure [34]. Furthermore, violent relationships increase women’s sexual risk taking behaviors and can 
impede efforts to negotiate safe sex practices, which are known to increase the risk of HIV exposure and 
infection [34]. 
IPV can be a major barrier to ART adherence, and thus must be addressed in HIV treatment and care 
programs [7]. Antenatal visits can provide a entry point for IPV screening [19]. Efforts to screen 
women for IPV have been received positively in other settings [35] and should be considered in the 
context of a maternal-health focused ART treatment program in South Africa. 
VIII. Gaps in research and contribution to the literature
Based on this review, no research exists on the risk of IPV specifically among women who are both 
pregnant and HIV-positive, however it has been well established that the risk of experiences of violence 
are pervasive in many subsets of this population, i.e. women in South Africa, pregnant women and HIV-
infected women. This research will shed light on the nature of these complex structures and how they 
coexist. This population represents a vulnerable group accessing health services with a complex and 
multi-level risk profile, and garnering further knowledge will help inform existing support services, 
17 	  
generate recommendations for expanding and enhancing existing support for IPV survivors, and guide 
future prevention programs. 
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Intimate partner violence among HIV-infected pregnant women initiating antiretroviral 
therapy in South Africa: a cross-sectional study 
Abstract 
Background 
Intimate partner violence (IPV) during pregnancy may be common in many settings where HIV is 
prevalent but there are few data on IPV in populations of HIV-infected pregnant women. We examined 
the prevalence and predicators of IPV among pregnant women initiating lifelong antiretroviral therapy 
(ART) in a primary care clinic in Cape Town, South Africa. 
Methods 
Consecutive pregnant women seeking antenatal care in Gugulethu, Cape Town were recruited into the 
MCH-ART study examining service models for postpartum ART care. IPV, depression, substance use  
and emotional distress were assessed using the 13 item WHO Violence Against Women questionnaire,  
the Edinburgh Postnatal Depression Scale (EPDS), alcohol and drug use disorders identification test 
(AUDIT/DUDIT) and the Kessler 10 (K-10) scale, respectively. Questionnaires were administered 
privately by trained interviewers. Women identified with specific IPV or mental health concerns were 
referred to appropriate services. Logistic regression was used to examine factors independently associated 
with experiences of IPV after adjusting for age and socioeconomic status. 
Results 
From April 2013-May 2014, 623 women were enrolled (median age, 28 years):97% were in a 
relationship, 38% were married and/or cohabiting and 70% reported not discussing or agreeing on 
pregnancy intentions prior to conception. Overall, 21%(n=132) reported experiencing ≥1 act of IPV in the 
past 12 months, including emotional(15%), physical(15%) and sexual violence(2%). Of those reporting 
any IPV, 48% reported experiencing multiple types. Emotional and physical violence were most prevalent 
among women 18-24 years old, while sexual violence was most commonly reported among women 25-29 
4 
years old. Women who reported not discussing or disagreeing on pregnancy intentions with their partners 
prior to conception were significantly more likely to experience violence(p=0.030), and women who 
experienced IPV reported higher levels of substance abuse, depression and emotional distress(p<0.001 for 
all associations). 
Discussion 
These data demonstrate high levels of IPV in this population. While the impact of HIV-infection, 
pregnancy and pregnancy intention on the risk of IPV and related factors require further research, IPV- 
related screening and support services should be considered as part of the package of care for ART in 
pregnancy. 
Keywords 
Intimate Partner Violence (IPV), Pregnancy, HIV, Women’s Health, Maternal Health, 
Antiretroviral Therapy, South Africa. 
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Intimate partner violence among HIV-infected pregnant women initiating antiretroviral 
therapy in South Africa: a cross-sectional study 
Background 
Intimate Partner Violence (IPV) is recognized as a major public health concern globally, associated with 
negative consequences for victims’ physical, mental, sexual and reproductive health[1–3]. Findings from 
a WHO multi-country study estimate that between 15% and 71% of women globally experience at least 
one act of physical and/or sexual IPV at some point in their lives[4]. 
The prevalence of IPV in sub-Saharan Africa is estimated to be over 30%, one of the highest in the world 
[1]. A systematic review of 13 studies of IPV in Africa found prevalence estimates to range from 2- 57%, 
with a meta-analysis prevalence of 15%[5]. Population based surveys and local research have shown that 
South Africa is no exception. The most recent South African population based survey conducted in 1998 
found 13% of women reported lifetime experiences of physical IPV, and 6% reported violence in the past 
year [6]. 
In many resource limited settings, women who experience IPV may be more likely to be young, of a low 
socioeconomic status, have limited education, have marital discord, and live in a community with high 
rates of poverty and low rates of female education[1, 3]. IPV is associated with a number of health 
sequelae, including: injury, disability, depression, emotional distress, alcohol and drug use, unintended 
pregnancy and an increased risk of HIV infection [1–4, 7]. 
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Research has provided evidence to support an association between IPV and HIV-infection in South 
Africa. Among women in Soweto, researchers found that seropositivity was significantly associated with 
experiences of violence (OR=1.48) and those with a history of IPV engaged in more sexual risk taking 
behaviors [8]. In another study of women attending community health centers, those who reported having 
violent or controlling partners were less likely to request condom usage and more likely to be HIV 
positive [9]. Power inequities present in violent relationships, and an inability to negotiate safe sex 
practices have been cited as contributing factors explaining the association between IPV and HIV- 
infection [1–3, 10]. 
The state of pregnancy is another component of the IPV structure, which is specifically and inherently 
gendered. The prevalence of IPV during pregnancy has been estimated at 1-28% in various sites 
worldwide [2]. While the effect of pregnancy on the risk of IPV is unclear [11, 12], data suggest that in 
lower- to middle-income country (LMIC) settings pregnancy most likely increases the risk of IPV [13]. 
In South Africa, nearly 25% of pregnant women in a study in Durban reported experiencing some type 
of IPV during pregnancy [14] and among women attending antenatal clinics outside of Cape Town 32%, 
28% and 14% reported experiencing emotional, physical and sexual violence in the past 12 months, 
respectively [13]. 
IPV has been shown to negatively affect women’s adherence to ART [15], as has emotional distress, a 
common comorbidity of IPV [14, 16]. A meta-analysis of ART adherence during pregnancy revealed 
that HIV-infected women face a unique set of challenges to ART adherence during pregnancy and post- 
partum periods, and a pooled analysis revealed that 73.5% of pregnant women had adequate ART 
adherence [17]. Poor ART adherence can have a number of adverse effects on both mothers and babies, 
including increased viral load, failure of treatment and MTCT of HIV [18]. 
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IPV is of particular note in the context of HIV and pregnancy. In 2010, over 30% of pregnant women 
presenting to public health facilities in South Africa were HIV positive [19]. While new policies in South 
Africa call for widespread use of antiretroviral therapy (ART) in pregnancy, IPV represents a potentially 
important barrier to ART adherence in this population, and thus efforts to better understand the risks and 
challenges they face, and the effect upon ART adherence is necessary to optimize ART care and improve 
maternal and child health outcomes. 
Evidence shows that IPV is occurring at high rates among both pregnant [13, 14] and HIV-infected [8–
10] populations in South Africa, however no known research on IPV among women who are both
pregnant and HIV- infected exists. This study aims to evaluate the prevalence and predictors of IPV, and 




An observational cohort study of 623 pregnant, HIV positive pregnant women was conducted as a part of 
a larger Maternal and Child Health Antiretroviral Treatment (MCH-ART) study aimed at evaluating the 
effectiveness of a MCH-focused ART treatment program in Cape Town, South Africa. Phase I of the 
study was a cross-sectional survey sampling from women arriving at the local clinic for an antenatal visit. 
Phase II participation was offered to a subset of phase I participants who were found to be ART-eligible 
according to local guidelines, and due to begin ART during their current pregnancy. Demographic data 
was collected during a 20-minute long measurement visit on the day of participants’ first antenatal clinic 
visit, while all other data was collected during a 30-45 minute long measurement visit on the same day as 
participants’ second antenatal clinic visit. 
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All participants signed informed consent forms before participation in both phases of the study. All 
consent forms and questionnaires were available in English and isiXhosa and were administered in 
participants’ language of choice. Staff underwent multiple training sessions to familiarize them with study 
protocols and procedures, including issues of confidentiality and referrals for unmet health needs and 
management of crisis situations. 
Measures 
Intimate Partner Violence was assessed using the WHO Violence Against Women questionnaire 
developed for the WHO multi-country study [4]. The 13-question measure asked whether participants had 
experienced specific acts of violence perpetrated by an intimate partner in the past 12 months. A positive 
response to any of the questions resulted in the participant being included in the total IPV prevalence 
count, with the specific type specified. There were four questions describing emotional violence, six 
describing physical violence, and three describing sexual violence. Distinctions between moderate and 
severe physical violence were based on the likelihood of the act of violence resulting in severe harm or 
injury to the victim. 
Socioeconomic status (SES) global measure was calculated using a number of markers of SES collected 
during participants’ demographic interview, including highest level of education, whether they were 
currently employed, whether formal employment was their main source of household income, housing 
type, number of household amenities and number of children living in the home. The scores were then 
categorized into three levels denoting low, middle and high SES. 
Relationship characteristics were self-reported by participants during their first antenatal clinic visit and 
referred to their current partners, if in a relationship. Questions were asked about relationship duration, 
marital status, partner cohabitation and whether a participant had disclosed her HIV status to her partner. 
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Participants were also asked about other sexual partners in the past 12 months. Women who reported 
being in a current relationship for more than a year and reported having had other sexual partners in the 
past year were confirmed as having engaged in concurrent partnerships in the past year. 
 
 
Pregnancy intention agreement data was sourced from one question of the London Measure of Unplanned 
Pregnancy [20] in which participants were asked if they had discussed with their partner and agreed to 
become pregnant before conception. 
 
 
Alcohol and drug use data were collected using the Alcohol Use Disorders Identification Test (AUDIT) 
[21] a 10-item scale, and Drug Use Disorders Identification Test (DUDIT) [22] scales, an 11-item scale, 
which screened for alcohol and drug use and alcohol- and drug-related problems, respectively. An 
AUDIT score of 8 or more was used to classify harmful alcohol use, while a DUDIT score of 2 or more 
denoted harmful drug use. Of the four participants who were classified as having harmful drug use, 
DUDIT scores were well above the cut-off point, ranging from 16 to 29. 
 
 
Emotional distress was measured using the Kessler-10 (K-10) scale [23], a 10-item measure regarding the 
extent to which participants deem their life to have been stressful in the last month. The Likert scale 




Depression was quantified using the Edinburgh Postnatal Depression Scale (EPDS) [24], a 10-item 
questionnaire that asked about feelings of sadness and depression during the past week. Likert scale 
responses were summed to generate an overall depression score. A score greater than or equal to 13 
classified participants as depressed. 
10 
Perceived availability of social support was a 12-item Likert scale questionnaire asking about the 
likelihood that participants would be supported or offered help by people in their lives should the need 
arise [25]. Responses were summed to get an overall score. If a participant scored above a 36 they were 
considered to perceive strong social support available to them. 
Ethics 
All data gathered for this study were obtained in a private setting, after participants gave informed 
consent and with due consideration for participants’ rights to confidentiality. Participants found to be 
experiencing IPV were referred to a local NGO offering counseling services and to the South African 
Police Service should they want to open a criminal case. The University of Cape Town Faculty of Health 
Sciences Human Research Ethics Committee and the Columbia University Medical Center Institutional Review 
Board granted approval for the initial data collection. Ethical clearance for the secondary analysis of study 
data was obtained from the University of Cape Town Faculty of Health Sciences Human Research Ethics 
Committee. 
Data Analysis 
Descriptive statistics of the outcome of interest and all predictor variables were reported for the total 
sample. Bivariate analyses were conducted using Z-statistics for continuous predictor variables, and X2 or 
Fisher’s Exact for binary predictor variables. All P-values were analyzed using a significance level of 
〈=0.05. Crude logistic regression models tested the association between total violence- defined as the
experience of any form or act of IPV in the last 12 months, and each predictor variable. Separate models 
were built to evaluate the association between IPV and relationship characteristics, and IPV and 
individual behavioral characteristics. A forward step-wise variable selection method was employed, using 
coefficient magnitude and significance levels to evaluate predictors. The process was then repeated in an 
analysis stratified by the time of participants’ first positive HIV test and an analysis stratified by couples’ 
pregnancy intentions prior to conception. All data analysis was done in Stata 12 (StataCorp. 2011. Stata 
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Statistical Software: Release 12. College Station, TX: StataCorp LP.) 
Results 
Women in the sample were between 18 and 44 years old, with a median age of 28 years. More than 
99.5% of participants identified as African and 97% reported isiXhosa as their home language. SES 
varied throughout the sample, with 35%, 31% and 34% reporting low, middle and high SES respectively. 
More than 97% of participants reported being in a current relationship, 25% were married and 41% were 
living with their partner. Over one third of participants (36%) had disclosed their HIV status to their 
partner. Relationship duration ranged from 3 months to 20 years, with a median duration of 3 years. 
Overall, 21% of the sample (132 women) reported experiencing at least one act of IPV in the past 12 
months. Specifically, 92 (15%) reported emotional violence, 96 (15%) reported moderate physical 
violence, of whom 43 (45% of those reporting any physical IPV and 7% of the overall sample) also 
reported severe physical violence, and 14 (2%) reported sexual violence. Of those who reported IPV 63 
participants (10% of the overall sample, 48% of those who reporting any IPV) experienced multiple types 
of violence in the last year (Figure 1). Emotional and physical violence was most prevalent among the 18- 
24 year olds, while sexual violence was most commonly reported among 25-29 year olds. 
Table 1 shows that women who reported IPV in the past year were less likely to be married (X2= 7.95, 
p=0.005) more likely to use drugs and/or alcohol (X2=44.32, p=0.000), report emotional distress 
(X2=23.10, p=0.000) and be depressed (X2=15.68, p=0.000). Those who experienced violence were also 
more likely to have not discussed pregnancy with their partners or not agreed with their partners to 
become pregnant prior to conception (X2=4.79, p=0.029) compared to women who had not experienced 
violence. 
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A logistic regression model of relationship characteristics adjusted for age and SES presented in Table 2 
found marriage and having a middle SES to be protective (OR=0.52 [0.30; 0.91], OR=0.61 [0.37;1.00] 
respectively). When modeling behavioral characteristics, being of middle SES (compared to low SES) 
was protective against IPV (OR=0.57 [0.34; 0. 94]) however women of a high SES were not significantly 
less likely to experience IPV compared to those of a low SES (OR=0.70 [0.42; 1.16]). Those who 
experienced IPV in the last year were also more likely to use drugs and/or alcohol (OR=4.61 [2.77; 7.69]), 
and report emotional distress (OR=2.37 [1.49; 3.76]) and depression (OR=2.07 [1.17; 3.69]). 
Overall, time of first HIV+ test was not a significant predictor of violence in the past year when adjusted 
for age and SES (OR=0.92 [0.62; 1.36]) (Table 2). Age and SES adjusted models of relationship 
characteristics stratified by time of first HIV+ test found that among women who first tested positive 
before this pregnancy, those who did not discuss pregnancy intentions with their partner or did not agree 
on pregnancy intentions with their partner prior to conception had significantly greater odds of 
experiencing IPV (2.44 [1.12; 5.31]). Among women who first tested HIV+ in this pregnancy, marriage 
was found to be protective against experiencing IPV (OR=0.29 [0.12;0.67]). Relationship duration was 
also found to be significant, but the odds ratio was negligible (OR=1.01 [1.00;1.02). 
Models of behavioral characteristics adjusted for age and SES and stratified by time of first HIV+ test 
found that those who experienced IPV in the last year were more likely to use alcohol and/or drugs, 
however the odds was lower among those who first tested HIV+ before this pregnancy compared to those 
who first tested HIV+ during this pregnancy (OR=3.36 [1.55; 7.29] vs. OR=6.36 [3.13; 12.94] 
respectively). Women who first tested HIV+ before this pregnancy were statistically significantly older 
than women who first tested HIV+ in this pregnancy (median ages 29 and 27 respectively, p=0.0000). 
Emotional distress was also more commonly reported among women who experienced violence, however 
the odds among those who first tested HIV+ before this pregnancy was higher than those who first tested 
HIV+ during this pregnancy (OR=2.75 [1.39; 5.43] vs. OR=2.13 [1.12; 4.06] respectively). Depression 
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was crudely associated with IPV in both strata, however became insignificant in the adjusted models 
(OR=2.15 [0.88; 5.24] among women who first tested HIV+ before this pregnancy and OR=1.96 [0.91; 
4.21] among women who first tested HIV+ in this pregnancy). Age was not significantly associated with 
experiences of IPV in any of the crude or adjusted models. 
Table 3 shows bivariate relationships according to pregnancy intention. Women who discussed pregnancy 
with their partners prior to conception and agreed to become pregnant were significantly less likely to 
experience violence overall (X2=4.79, p=0.029) and physical violence (X2=6.68, p=0.010). They were 
more likely to be in a relationship (p=0.030) for longer (Z=3.76, p=0.0002), and to be cohabitating with 
their partner (X2=45.62, p=0.000) but less likely to be married (X2=7.95, p=0.005) compared to women 
who had either not discussed or not agreed to become pregnant with their partners prior to conception. 
Logistic regression models of relationship characteristics stratified by pregnancy intention (Table 4) show 
that among women who discussed and agreed to become pregnancy prior to conception, those who 
reported violence n the past year had lower odds of being married (OR=0.22 [0.08;0.61). Among women 
who did not discuss or disagreed there were not statistically significant predictors of experiencing IPV in 
the last 12 months. 
Models of behavioral characteristics show that among women who discussed and agreed to become 
pregnant with their partner, those who reported violence were significantly more likely to be substance 
users (OR=5.31 [1.95;14.43]) compared to those who did not report violence. Among women who did not 
discuss or disagreed on pregnancy intentions prior to conception, those who reported IPV were 
significantly more likely to use substances (OR=4.98 [2.66;9.31]), report emotional distress (OR=2.52 
[1.47;4.31]) and depression (OR=2.08 [1.06;4.09]). 
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Discussion 
These data show a significant burden of IPV in this population, with 21% reporting IPV in the 
past 12 months, 15% reporting physical and emotional violence respectively and 2% reporting 
sexual violence. Of those who reported violence, 48% experienced multiple types, most often 
physical and emotional violence together (37% of those who reported any IPV and 8% of overall 
sample). Women who experienced violence were more likely to be unmarried, substance users, 
emotionally distressed and depressed. Women who reported pregnancy intention discord with 
their partner were more likely to experience violence, and among those who experienced 
violence substance use, emotional distress and depression were reported more often. 
The estimated prevalence of overall IPV in this sample (21%) is the same as a previously 
reported study of IPV during pregnancy [26], and only slightly lower than the 24.75% prevalence 
reported among pregnant women in Durban [14]. It is, however, markedly higher than the most 
recent population-based data gathered in the 1998 South African Demographic and Health 
Survey (SADHS), in which 4% of women reported IPV during pregnancy [6]. It is worth noting, 
however, that underestimation has been noted in these data, and a study conducted in the Eastern 
Cape using the same enumeration area used in the SADHS reported a prevalence of 27% of ever-
partnered women reporting physical IPV, compared to the 9% found in the same area by the 
SADHS [6]. Furthermore, underreporting is common in this field of research [6], and thus it is 
plausible that the true prevalence of IPV in this population is higher than the estimates produced 
by these data. 
The reported prevalence of sexual IPV in this sample was markedly lower than the other types of 
IPV (2%), however consistent with previous research in which 3% of women in South Africa 
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reported sexual IPV during pregnancy [26]. A multi-country study published by the WHO 
reported that in most sites, between 4% and 12% of women experience IPV during pregnancy 
[27]. Although these estimates are slightly lower than those reported in previous South African 
settings [26], they still represent a significant burden of disease in this population. 
Overall, demographic and relationship characteristics did not appear to be strong predictors of 
IPV, as is consistent with past systematic reviews from the region which have reported mixed 
findings on the role of such variables on the, if any, on the risk of IPV [26]. Age was not 
statistically significant in any adjusted regression models presented, and SES was insignificant in 
nearly all presented models. While age has been noted as a significant predictor in some past 
research, in many cases it does not significantly predict IPV [28]. Poverty has been consistently 
associated with IPV in past research [28]. However, in a setting such as this in which there is 
such a high prevalence of IPV, and in which the vast majority are relatively impoverished, we 
hypothesize that there is not enough SES variability to see the association that may exist between 
poverty and IPV in these data. 
Similarly, relationship characteristics were non-predictive across most models, with no more 
than two individual factors ever being significantly associated with the reported experience of 
IPV in any particular model, and no specific relationship characteristic remaining statistically 
significant across all models. Behavioral characteristics, however, were consistently predictive. 
Substance use was statistically significantly associated with an increased risk of IPV in all six 
models presented, and emotional distress and depression were often associated with reported 
experiences of IPV, as consistent with previous research [14, 29–31]. 
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These data showed no major differences in the associated behavioral characteristics among 
women who first test HIV positive before this pregnancy compared to those who first tested HIV 
positive during this pregnancy. While there were differences in the associated relationship 
characteristics between the two groups, we do not believe they represent a fundamental 
difference in the risk profile of women who were previously aware of their HIV status compared 
to those who have recently been diagnosed. 
Results show that women who reported IPV in the last 12 months are more likely to have either 
not discussed or not agreed with their partners to become pregnant prior to conception. 
Additionally, logistic regression models show that among women who do not discuss or agree 
with their partners regarding pregnancy, those who experience IPV are significantly more likely 
to also report substance use, emotional distress and depression. All of these factors are known to 
impede ART adherence among pregnant women [17], and are thus a major barrier in optimizing 
care in this population. Local research has shown that IPV screening and identification in 
primary care settings in South Africa is very low [32], however IPV survivors participating in a 
study to evaluate an IPV screening and management protocol reported significant improvements 
in their mental health, substance use, partner relationships as a result of screening and referrals 
[33]. Therefore, querying women’s pregnancy intentions within the context of a maternal 
health-focused ART program is a potentially important screening tool for both IPV and other 
comorbidities which can have an adverse effect on women’s ART care, and thus on the health 
of both mothers and children. 
This analysis is subject to a number of important limitations. This is a cross-sectional study and 
therefore cannot establish temporality between IPV and associated risk factors. In order to better 
17 
understand the cycle of violence and how it manifests in this population, one must understand 
whether specific relationship and behavioral factors increase the risk of IPV, or vice versa. From 
these data it is not possible, for instance, to know if experiences of IPV lead to depression, or if 
depression increases a woman’s risk of IPV. Furthermore, the nature of the WHO questionnaire 
used to measure IPV does not allow researchers to establish the frequency of violence acts, nor 
the time period in relation to current pregnancy. More detailed information regarding violence 
before, during and after pregnancy specifically would shed more light on the effects of 
pregnancy on the risk of IPV. In addition, underreporting is a common bias in this type of 
research, due to the sensitivity and stigma often associated with violence [6, 26]. However, 
reports of sexual violence appear drastically lower than many previous findings. Although 
pregnancy has been shown to be protective against IPV in some settings [11] this discrepancy is 
more than likely a result of methodological issues or biases. It is well documented that IPV, 
especially of a sexual nature, is a major source of shame and stigma that may be a barrier to 
reporting [6]. 
However, while there are limitations, this is also the first known research looking at IPV risk 
profiles specifically among women with two previously established risk factors of IPV- 
pregnancy and HIV-infection. The high prevalence estimates garnered from these data suggest 
that IPV is a significant burden on this population, and warrants further research. Prospective 
studies are necessary to establish temporality between IPV and predictive factors, and to 
estimate the incidence of IPV. Furthermore, prospective studies will allow further assessment of 
the effects of pregnancy and HIV-infection on IPV, and the role of IPV in ART adherence and 
retention. 
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Future research also must place an emphasis on programs and practices for IPV prevention, and 
further research into the possible role of pregnancy intention agreement as a screening tool for 
IPV is warranted. While screening alone does not reduce IPV risk, screening and paired 
interventions have be shown to significantly lower future risk of IPV [26], including one 
program showing efficacy in South Africa [34]. It is estimated that 87% of pregnant women in 
South Africa attend at least four antenatal visits [26], thus interventions in maternal health 
settings, specifically those geared towards HIV-infected women, offer an ideal point of access to 
this highly vulnerable population. 
This research has number of implications for changing policies and public health programs in 
South Africa. Health care workers, especially those working in HIV- and pregnancy-related 
fields, need to be adequately trained in identifying and referring IPV survivors to appropriate 
services. Information regarding IPV and local support services should be integrated into all 
maternal health and HIV pamphlets and educational materials, and be kept readily available in 
health centers. Local support services must be supported and expanded in order to meet the 
increased burden of disease identified through screening efforts. Furthermore, interdisciplinary 
stakeholders must be mobilized on a national level to become more involved raising awareness, 
supporting prevention programs and adapting IPV policies and programs nationally. Finally, 
screening and support services for IPV must be integrated into ART programs across South 




In summary, these data demonstrate a high prevalence of IPV- specifically physical and 
emotional violence - in this population of HIV-infected pregnant women. The prevalence of IPV 
in this study suggests that this is a high-risk population accessing health services requiring 
continued efforts to further understand and optimize care. While the potential impact of IPV and 
related factors on ART adherence over time require further research, IPV-related screening and 
appropriate support services need to be considered as part of the package of care for ART in 
pregnancy. 
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Figure 1: Venn diagram of types of violence experienced in past 12 
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Tables 
Table 1: Bivariate analysis of socioeconomic, relationship and behavioral characteristics by IPV 














OR n (%) 
Med (IQR) 
OR n (%) 
Med (IQR) 




Emotional Violence 92 (15%) 
Physical Violence 96 (15%) 
Sexual violence 14 (2%) 
Age 28 (24-32) 28 (24-31) 28 (25-32) 1.180 0.237 
SES Global Measure (3 levels) 3.17 0.205 
Low 184 (30%) 46 (35%) 138 (28%) 
Middle 230 (37%) 41 (31%) 189 (39%) 
High 209 (34%) 45 (34%) 164 (33%) 
Currently in a relationship 606 (97%) 125 (95%) 481 (98%) ----- 0.064 
Duration of relationship (years) (n=623) 3 (2-5) 2.25 (1.63-5) 3 (2-5) 1.09 0.275 
HIV status disclosure to partner (n=606) 217 (36%) 44 (35%) 173 (36%) 0.03 0.870 
Married to partner (n=606) 151 (25%) 19 (15%) 132 (28%) 7.95 0.005 
Cohabitating with partner (n=606) 246 (41%) 44 (35%) 202 (42%) 1.90 0.168 
Confirmed concurrency in past 12 months 55 (9%) 13 (10%) 42 (9%) 0.22 0.642 
Boyfriend 36 (6%) 9 (7%) 28 (6%) 
Casual partner 19 (3%) 5 (4%) 14 (3%) 
HIV status disclosure to concurrent 
partners (n=55) 
16 (16%) 4 (16%) 12 (16%) ----- 0.59 
AUDIT/DUDIT 
# reporting harmful drug or alcohol use 81 (13%) 40 (30%) 41 (8%) 44.32 0.000 
Kessler-10 scale 
# reporting distress 132 (21%) 48 (36%) 84 (17%) 23.10 0.000 
EPDS scale 
# reporting depression 68 (11%) 27 (20%) 41 (8%) 15.68 0.000 
PAS scale (n=621) 
# reporting perceived social support 515 (83%) 113 (86%) 402 (82%) 1.30 0.254 
Pregnancy intention agreement with 
partner (n=614) 
5.82 0.055 
Discussed, agreed to become pregnant 185 (30%) 29 (22%) 156 (32%) ----- ------ 
Did not discuss or disagreed 429 (70%) 101 (78%) 328 (68%) 4.79 0.029 
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Table 2: Logistic regression of the risk of experiencing IPV in past 12 months stratified by time 
of first HIV+ test 
TOTAL (n=623) TESTED HIV+ BEFORE THIS 
PREGNANCY (n=281) 
FIRST TESTED HIV+ IN THIS 
PREGNANCY (n=342) 
ADJUSTED 
OR 95% CI P-value
Testing HIV+ in this 
pregnancy 
0.92 (0.62-1.36) 0.670 
ADJUSTED ADJUSTED ADJUSTED 
OR 95% CI P-value OR 95% CI P-value OR 95% CI P-value
Relationship characteristics 
Age 0.99 (0.95-1.03) 0.548 0.98 (0.92-1.04) 0.471 0.96 (0.91-1.02) 0.175 
SES 
Low --- --- --- --- --- --- --- --- --- 
Middle 0.63 (0.39-1.03) 0.065 0.74 (0.36-1.54) 0.422 0.53 (0.27-1.03) 0.061 
High 0.76 (0.47-1.25) 0.284 1.17 (0.57-2.42) 0.668 0.60 (0.31-1.15) 0.125 
Duration 1.01 (1.00-1.02) 0.008 
Marriage 0.52 (0.30-0.90) 0.020 0.29 (0.12-0.67) 0.004 
Pregnancy intention 
Discussed, agreed --- --- --- --- --- --- --- --- --- 
Did not discuss or 
disagreed 
1.33 (0.82-2.15) 0.244 2.44 (1.12-5.31) 0.025 
Behavioral characteristics 
Age 0.99 (0.95-1.03) 0.528 1.00 (0.94-1.07) 0.994 0.99 (0.94-1.03) 0.602 
SES 
Low --- --- --- --- --- --- --- --- --- 
Middle 0.57 (0.3- 0.94) 0.029 0.53 (0.24-1.16) 0.110 0.62 (0.31-1.24) 0.177 
High 0.70 (0.42-1.16) 0.162 0.76 (0.36-1.64) 0.492 0.65 (0.33-1.29) 0.219 
Alcohol/Drugs 4.61 (2.77-7.69) 0.000 3.36 (1.55-7.29) 0.002 6.36 (3.13-12.94) 0.000 
Distress 2.37 (1.49-3.76) 0.000 2.75 (1.39-5.43) 0.004 2.13 (1.12-4.06) 0.022 
Depression 2.07 (1.17-3.69) 0.013 2.15 (0.88-5.24) 0.092 1.96 (0.91-4.21) 0.086 
29 
Table 3: Bivariate analysis of IPV experiences, socioeconomic, relationship and behavioral 

















OR n (%) 
Med (IQR) 
OR n (%) 
Med (IQR) 




Pregnancy intention agreement with partner 
prior to conception (n=614) 
Discussed, agreed to become pregnant 185 (30%) 
Did not discuss or disagreed 429 (70%) 
Total Violence 130 (21%) 29 (16%) 101 (24%) 4.79 0.029 
Emotional Violence 90 (15%) 21 (11%) 69 (16%) 2.31 0.128 
Physical Violence 95 (15%) 18 (10%) 77 (18%) 6.68 0.010 
Sexual Violence 14 (2%) 3 (2%) 11 (3%) ----- 0.569 
Age 28 (24-32) 28 (24-31) 28 (24-32) 0.25 0.804 
SES Global Measure (3 levels) 1.78 0.410 
Low 184 (30%) 50 (27%) 134 (31%) 
Middle 226 (37%) 67 (36%) 159 (37%) 
High 204 (33%) 68 (37%) 136 (32%) 
Currently in a relationship 597 (97%) 184 (99%) 413 (96%) ----- 0.030 
Duration of relationship (years) 3 (2-5) 4 (2-6) 3 (1.17-5) 3.76 0.0002 
HIV status disclosure to partner (n=597) 213 (36%) 72 (39%) 141 (34%) 1.38 0.240 
Married to partner (n=597) 150 (25%) 19 (15%) 132 (28%) 7.95 0.005 
Cohabitating with partner (n=597) 242 (41%) 112 (61%) 130 (32%) 45.62 0.000 
Confirmed concurrency in past 12 months 52 (8%) 20 (11%) 32 (7%) 1.87 0.171 
Boyfriend 34 (6%) 11 (2%) 23 (4%) 
Casual partner 18 (3%) 9 (1%) 9 (1%) 
HIV status disclosure to concurrent partners 
(n=52) 
6 (12%) 1 (5%) 5 (16%) ----- 0.387 
AUDIT/DUDIT 
# reporting harmful drug or alcohol use 79 (13%) 25 (14%) 54 (13%) 0.10 0.753 
Kessler-10 scale 
# reporting distress 129 (21%) 32 (17%) 97 (23%) 2.20 0.138 
EPDS scale 
# reporting depression 65 (11%) 14 (8%) 51 (12%) 2.55 0.110 
PAS scale (n=612) 
# reporting perceived social support 507 (83%) 151 (82%) 356 (83%) 0.28 0.598 
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Table 4: Logistic regression of the risk of experiencing IPV in past 12 months stratified by 
pregnancy intention 
 
	   TOTAL (n=614) 	   DISCUSSED AND AGREED 
(n=185) 




	   ADJUSTED 	   	   	   	  
	   OR 95% CI P-value 	   	   	   	  
Pregnancy Intention 	   	   	   	   	   	   	  
Discussed, agreed --- --- --- 	   	   	   	  
Did not discuss or 
disagreed 
1.65 (1.04-2.60) 0.032 	   	   	   	  
	   	   	   	   	   	   	   	  
	  
	   ADJUSTED 	   ADJUSTED 	   ADJUSTED 
	   OR 95% CI P-value 	   OR 95% CI P-value 	   OR 95% CI P-value 
	  
Relationship characteristics 
Age 0.99 (0.95-1.03) 0.535 	   0.97 (0.90-1.05) 0.503 	   0.98 (0.94-1.03) 0.436 
SES 	   	   	   	   	   	   	   	   	   	   	  
Low --- --- --- 	   --- --- --- 	   --- --- --- 
Middle 0.61 (0.37-1.00) 0.048 	   0.42 (0.13-1.31) 0.33 	   0.73 (0.42-1.26) 0.252 
High 0.74 (0.45-1.22) 0.243 	   1.02 (0.39-2.72) 0.962 	   0.68 (0.38-1.22) 0.198 
Disclosure to Partner 	   	   	   	   	   	   	   	   1.26 (0.78-2.04) 0.338 
Marriage 0.52 (0.30-0.91) 0.022 	   0.22 (0.08-0.61) 0.004 	   	   	   	  
	  
Behavioral characteristics 
Age 0.99 (0.95-1.03) 0.528 	   1.01 (0.93-1.09) 0.861 	   0.99 (0.94-1.03) 0.531 
SES 	   	   	   	   	   	   	   	   	   	   	  
Low --- --- --- 	   --- --- --- 	   --- --- --- 
Middle 0.58 (0.35- 0.97) 0.039 	   0.40 (0.13-1.29) 0.125 	   0.60 (0.34-1.08) 0.090 
High 0.69 (0.42-1.15) 0.157 	   1.12 (0.42-2.96) 0.825 	   0.57 (0.31-1.04) 0.067 
Alcohol/Drugs 4.66 (2.78-7.80) 0.000 	   5.31 (1.95-14.43) 0.001 	   4.98 (2.66-9.31) 0.000 
Distress 2.29 (1.44-3.64) 0.000 	   	   	   	   	   2.52 (1.47-4.31) 0.001 
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Appendix P1: Phase 2 informed consent form 
 
Phase 2 Informed Consent Form 
 
TITLE OF RESEARCH: Strategies to optimize antiretroviral therapy 




WHAT IS THE PURPOSE OF THIS STUDY? 
We are from the University of Cape Town and ICAP at Columbia University. You are being 
asked to take part in a study that is being conducted at the Gugulethu Midwife Obstetric Unit 
(MOU). The purpose of this study is to understand how to improve health care services for HIV- 
positive women during their pregnancy and after they deliver the baby. 
 
We know that it is important for their own health as well as the health of their baby, that HIV- 
positive women receive the HIV care and treatment that they need both during and after delivery. 
Information learned in this study will help us to improve HIV services for pregnant women. 
 
You are being asked to take part in this study because you are a pregnant woman with known 
HIV infection who is about to start taking HIV drugs (antiretroviral therapy) and you took part in 
the first phase of the study. The purpose of this consent form is to give you information to help 
you decide if you want to take part in the next phase of this study. 
 
 
WHAT DO I HAVE TO DO IF I AGREE TO TAKE PART? 
If you agree to take part, you will come in for up to 3 visits. These visits will take place today 
while you are in the clinic, when you are getting close to delivering your baby and within one 
week of delivering your baby. These study visits are separate from the usual clinic visits that you 
will have for your pregnancy and HIV care. Study visits will be timed so that they take place on 
the same days that you come in for your usual pregnancy and/or HIV care.Each visit will take 
about 30-45 minutes. 
 
At the two visits that are conducted while you are pregnant, you will do the following: 
• Answer questions about your recent pregnancy- and HIV-related health care, HIV 
disclosure, and use of HIV drugs (including side effects and adherence). 
o At different visits, we will ask you additional questions about HIV, stigma, social 
support, infant feeding practices, family planning, experiences of partner 
violence, and mental health (including drug and alcohol use). 
• Have 5mLs (1 teaspoon) of blood drawn from your arm each time 
 
One-week after delivery 
One week after you give birth to your baby, you will come to the clinic for a visit that will 
include the following: 
• Answer questions about your recent pregnancy- and HIV-related health care, HIV 
disclosure, and use of HIV drugs (including side effects and adherence). 
o At this visit, we will ask you additional questions about family planning after 
delivery, how you felt about the HIV care that you received, infant feeding 
practices and infant health and health care. 
• Have 5mLs (1 teaspoon) of blood drawn from your arm 
 
Page 1 of 5 




   
    
    
      
   
    
6 
	  
Phase 2 Informed Consent Form 
 
 
NOTE: The blood that is drawn today will be stored and used to check your viral load (this is the 
amount of HIV in your blood) at a later time. Results from these tests will not be available to 
you, the clinic, or the study staff. When the health care providers at the clinic need to check your 
viral load, they will take a separate blood specimen. When it is stored, your blood and test results 
will not have your name or any other way of identifying you attached to it. 
 
Follow-up of missed visits 
You will be asked to provide contact information so that we may get in touch with you during  
the study. Study staff will talk with you about the best way to contact you. In the event that you 
miss one of the scheduled study visits, a member of the study staff will contact you in order to 
find another day and time to complete your visit. If you repeatedly miss study visits or the staff is 
unable to contact you using the information that you provide, it may be necessary to visit you at 
home in order to reschedule the missed study visit. 
 
Contact for future study 
After the completion of the visit one week after delivery, it is possible that we will contact you 
again at your next clinic visit or at another time in the future to take part in additional research 
studies. At that time, you would be asked to review and sign another consent form. You can 
choose to not take part in any future studies if you are asked. You will be asked to provide 
contact information so that we may get in touch with you regarding additional research studies. 
Study staff will talk with you about the best way to contact you. 
 
WHAT ARE THE POTENTIAL RISKS? 
You may feel uncomfortable about some of the personal questions you are asked. You may 
refuse to answer any question that you do not want to answer. There is some risk in sharing 
personal and medical information. We will be careful to keep all your information as private as 
possible. 
 
Drawing blood is normally done as part of routine medical care and presents a slight risk of 
discomfort. Experienced staff will draw blood under sterile conditions in order to protect you 
against these risks. 
 
 
WHAT ARE THE POTENTIAL BENEFITS? 
There is no direct benefit to you if you take part in this study. The information gained in this 
study may help to improve ART services for HIV-infected pregnant women in Cape Town, the 
Western Cape Province, and across South Africa. 
 
 
WHAT ARE THE ALTERNATIVES TO TAKING PART? 
The alternative to taking part in this study is to continue with your usual care at the MOU. 
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Phase 2 Informed Consent Form 
 
WHAT ABOUT CONFIDENTIALITY? 
If you agree to take part, all information collected during the study will be kept strictly 
confidential. Your name will not be written on the study forms and will not be used in 
connection with any information or lab specimens that are collected as part of the study. 
 
All study materials will be stored in locked filing cabinets. Only study staff and personnel 
involved in routine audits will have access to these materials. All staff involved in data collection 
and management will get specific training in confidentiality. 
 
Even with these procedures in place, if the study staff learns that you are a risk to yourself or 
someone else or of possible child abuse and/or neglect, study staff will tell the proper authorities. 
 
 
WILL I BE GIVEN ANYTHING FOR TAKING PART? 
At the end of each visit, you will be given R20 in cash to cover the transport cost to your next 
scheduled study visit, and anR80grocery voucher. You will also receive a small gift for the first 
visit after birth and refreshments will be provided at all visits. 
 
 
ARE THERE ANY COSTS? 
There is no cost for being in this study. 
 
 
CAN I LEAVE THE STUDY? 
You have the right to decide not to not take part in the study, to refuse to answer any questions, 
or to withdraw from the study at any time without any penalty. It will have no effect on the care 
that you receive at the Gugulethu MOU or any other health facility. 
 
 
FUTURE USE OF SPECIMENS: 
If you agree, any leftover blood from the samples you have provided for this research project 
may be used for future HIV related research. It is possible that these stored samples may be 
tested to see if the HIV in your blood is resistant to any types of HIV medications or to look at 
other questions related to HIV. 
 
At this time, we cannot provide details of when this testing may be conducted. However, 
additional testing will not be done using these stored samples without the approval of the 
appropriate ethics committees involved in this research. 
 
If you agree to let us keep your stored samples for future research, they may be kept in a locked 
freezer for up to 5 years. If we do use your samples in the future, your name or other identifiers 
will not be included with this information (as with the rest of the information we collect for this 
study). 
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Phase 2 Informed Consent Form 
 
Please initial below to indicate whether or not you give permission for your specimens to be used 
for future research. You may still remain in the study, no matter which you choose. 
 
 
  (initial) I agree to have my blood stored for future research. 
 
 
  (initial) I agree to have my blood stored for future research related to this study ONLY. 
 
 
  (initial) I do NOT agree to the storage of my blood for future use. 
 
 
DO YOU HAVE ANY QUESTIONS? 
If there is anything that is unclear or if you need further information, please ask us and we will 
provide it. 
Do you have any questions? 
 
 
FOR ADDITIONAL INFORMATION: 
If you have any questions or have any problems while taking part in this research study, you 
should contact: 
 
Dr Landon Myer Dr Elaine Abrams 
School of Public Health and Family Medicine ICAP, Columbia University 
Faculty of Health Sciences, University of 
Cape Town 
Tel: 021 406 6661 
Email: Landon.Myer@uct.ac.za 
Mailman School of Public Health 
College of Physicians and Surgeons 
Tel: +1 212 342 0543 
Email: eja1@columbia.edu 
 
If you have any questions about your rights as a research participant, you may contact the 
following member of the ethics committee: 
 
Prof Marc Blockman Columbia University Medical Center IRB 
Chair, Human Research Ethics Committee Tel: +1 212 305 5883 
Faculty of Health Sciences, University of Cape 
Town 
Tel: 021 406 6338 
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Phase 2 Informed Consent Form 
 
CONSENT STATEMENT: 
I have read this form, or someone has read it to me. I have been offered a copy of this consent 
form. I was encouraged and given time to ask questions. I agree to be in this study. I know that 
after choosing to be in this study, I may withdraw at any time. My being in the study is 
voluntary. I understand that whether or not I participate will not affect my health care services 
received today, or at any time in the future. 
 
 
Please indicate your consent with your signature. 
 













Signature of study staff Date 
 
 
If the volunteer is unable to read or write the entire counselling process must be observed 










I confirm that I am independent of the study and that I witnessed the entire informed consent 
counselling process in the home language of the volunteer 
 
 
Name:   
 
Signature:    
 





	   	   	   	  
Appendix P2: WHO violence against women questionnaire 
 
MCH-ART: Trauma/ Abuse assessment Phase 2 1st  visit PID: 2 -                     -          
Xhosa-English Version 2.1, 28 Jan 2013 
 
WHO VAW QUESTIONNAIRE Visit Date:          /              /                  
Siza kubuza imibuzo embalwa malunga nokuhlukunyezwa kwako liqabane lako. 
We are going to ask you a few questions relating to partner violence. 
 
Kwezi nyanga zi-12 zidlulileyo ukhe wafunyanwanzezi zilandelayo 
In the last 12 months, have you experienced any of the following? 







1. Iqabane lakho likhe lakuthuka okanye wasiva ungalunganga? 







Likhe lakwenza wasifumanisa ukuba usithobile isidima sakho phambi 
kwabanye abantu? 






3. Likhe laoyikisa lakuphatha kakubi ngabom 






4. Likhe lakugrogrisa ngokonzakalisa okanye umntu omnakekelayo? 













Likhe lakuqhwaba ngempama okanye wakugibisela ngento 
enokwenzakalisa? 





6. Likhe lakutyhala okanye lakunyola? 
Has he pushed or shoved you? 
1 0 
7. Likhe lakubetha ngenqindi okanyengento enokonzakalisa? 
Has he hit you with a fist or with something else that could hurt you? 
1 0 
8. Likhe likukhabe,likurhuqe okanye likubethe? 
Has he kicked you, dragged you or beaten you up? 
1 0 
9. Likhe likukrwitshe okanye likutshise ngabom? 




Likhe likugrogrise okanye lisebenzise umpu,imela okanye nasiphi 
isixhobo kuwe? 











11. Likhe likunyanzele ngokwabelana ngocantsi wena ungafuni? 




Wakhe wabelana naye ngocantsi ungafuni kuba uloyika umazi 
angenza ntoni? 








Likhe likunyanzele ngokwebelana ngocantsi ngendlela ofumanisa ukuba 
ukuthathela phantsi okanye uyakwenyelisa? 






Date completed:           /__           /                   Signed counsellor completing CRF:    
 
Date of QC:           /__           /                   Signed measurement nurse:    
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Appendix M1: Reported experiences of IPV in the past 12 months 
 
	   n (%) 
	   	  
Total Violence 132 (21%) 
	   	  
Emotional violence 92 (15%) 
Insulted you 69 (11%) 
Belittled/humiliated you 48 (8%) 
Scared/intimidated you on purpose 30 (5%) 
Threatened to hurt you or someone you care about 24 (%) 
Physical violence 96 (15%) 
Moderate Physical Violence 	  
Slapped or thrown something at you 85 (14%) 
Pushed/shoved you 57 (9%) 
Hit you with a fist or something else that could hurt you 27 (4%) 
Severe Physical Violence 43 (7%) 
Kicked you, dragged you or beaten you up 28 (5%) 
Chocked or burned you on purpose 18 (3%) 
Threatened to use or used a gun, knife or other weapon against you 8 (1%) 
Sexual Violence 14 (2%) 
Physically forced you to have sexual intercourse when you didn't want to 14 (2%) 
Unwanted sexual intercourse because you were afraid of what he might do 8 (1%) 
Forced to do something sexual you found degrading or humiliating 5 (1%) 
13 
Appendix M2: Reported experiences of IPV by age 






























Total Violence 132 (21%) 40 (25%) 45 (20%) 33 (19%) 14 (19%) 
Emotional violence 92 (15%) 28 (18%) 30 (14%) 23 (14%) 11 (15%) 
Insulted you/made you feel bad 69 (11%) 23 (14%) 20 (9%) 17 (10%) 9 (12%) 
Belittled/humiliated you 48 (8%) 14 (9%) 17 (8%) 11 (6%) 6 (8%) 
Scared/intimidated you on purpose 30 (5%) 8 (5%) 7 (3%) 10 (6%) 5 (7%) 
Threatened to hurt you or someone 
you care about 
24 (4%) 5 (3%) 7 (3%) 8 (5%) 4 (6%) 
Physical violence 96 (15%) 31 (20%) 30 (14%) 25 (15%) 10 (14%) 
Moderate Physical Violence 
Slapped or threw something at you 85 (14%) 26 (17%) 26 (12%) 23 (14%) 10 (14%) 
Pushed/shoved you 57 (9%) 19 (12%) 18 (8%) 14 (8%) 6 (8%) 
Hit you with a fist or something 
else that could hurt you 
27 (4%) 6 (4%) 8 (4%) 9 (5%) 4 (5%) 
Severe Physical Violence 43 (7%) 14 (9%) 13 (6%) 11 (6%) 5 (7%) 
Kicked you, dragged you or beaten 
you up 
28 (5%) 11 (7%) 8 (4%) 7 (4%) 2 (3%) 
Chocked or burned you on purpose 18 (3%) 5 (3%) 6 (3%) 6 (4%) 1 (1%) 
Threatened to use or used a gun, 
knife or other weapon against you 
8 (1%) 4 (3%) 1 (0.5%) 3 (2%) 0 
Sexual Violence 14 (2%) 1 (1%) 9 (4%) 3 (2%) 1 (1%) 
Physically forced you to have 
sexual intercourse when you didn't 
want to 
14 (2%) 1 (1%) 9 (4%) 3 (2%) 1 (1%) 
Unwanted sexual intercourse 
because you were afraid of what 
he might do 
8 (1%) 0 5 (2%) 2 (1%) 1 (1%) 
Forced to do something sexual you 
found degrading or humiliating 
5 (1%) 1 (1%) 3 (1%) 0 1 (1%) 
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Appendix M3: Bivariate analysis of relationship characteristics by types of reported IPV 
Reported 
violence in 
past 12 months 
(n=132) 
Did not report 
violence in 





OR n (%) 
Median (IQR) 
OR n (%) 
Mean (SD) 




Duration of relationship (years) (n=623) 
Total IPV 2.25 (1.63-5) 3 (2-5) 3 (2-5) 1.09 0.275 
Physical IPV 2 (1.63-5) 3 (2-6) 3 (2-5) 1.57 0.12 
Emotional IPV 3 (1.04-6) 3 (2-5) 3 (2-5) 0.46 0.65 
HIV status disclosure to partner (n=606) 
Total IPV 44 (35%) 173 (36%) 217 (36%) 0.03 0.870 
Physical IPV 36 (41%) 181 (35%) 217 (36%) 0.98 0.32 
Emotional IPV 27 (31%) 190 (37%) 217 (36%) 0.85 0.36 
Married to partner (n=606) 
Total IPV 19 (15%) 132 (28%) 151 (25%) 7.95 0.005 
Physical IPV 13 (15%) 138 (27%) 151 (25%) 5.93 0.02 
Emotional IPV 17 (20%) 134 (26%) 151 (25%) 1.42 0.23 
Cohabitating with partner (n=606) 
Total IPV 44 (35%) 202 (42%) 246 (41%) 1.90 0.168 
Physical IPV 29 (33%) 217 (42%) 246 (41%) 2.78 0.10 
Emotional IPV 35 (41%) 211 (41%) 246 (41%) 0.00 0.98 
Confirmed Concurrency in last 12 
months (n=623) 
Total IPV 13 (10%) 42 (9%) 55 (9%) 0.22 0.642 
Physical IPV 10 (10%) 45 (9%) 55 (9%) 0.36 0.551 
Emotional IPV 9 (10%) 46 (9%) 55 (9%) 0.12 0.727 
Pregnancy Intention Agreement (n=614) 
Total IPV 29 (22%) 156 (32%) 185 (30%) 4.79 0.029 
Physical IPV 18 (19%) 167 (32%) 185 (30%) 6.68 0.010 
Emotional IPV 21 (23%) 164 (31%) 185 (30%) 2.31 0.128 
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Med (IQR) Med (IQR) Med (IQR) Z-Stat P-value
Age 29 (26-32) 27 (23-31) 28 (24-32) -4.448 0.0000 
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Appendix M5: Relationship characteristics associated with experiences of IPV in the past 






d for all 
variable
s
OR 95% CI OR 95% CI 
Age 0.97 (0.93;1.02) 
SES 
Low ----- ----- ----- ----- 
Middle 0.72 (0.42;1.23) 
High 0.80 (0.47;1.36) 
Disclosure 1.06 (0.68;1.66) 
Duration 1.00 (1.00;1.01) 1.01 (1.00;1.00) 
Marriage 0.48 (0.27;0.86) 0.41 (0.22;0.75) 
Cohabitation 0.75 (0.47;1.19) 
Concurrency 0.97 (0.48;1.98) 
Pregnancy intention 
Discussed, agreed ----- ----- ----- ----- 




Appendix M6: Relationship characteristics associated with experiences of IPV in the past 






d for all 
variable
s
OR 95% CI OR 95% CI 
Age 1.00 (0.90;1.10) 
SES 
Low ----- ----- ----- ----- 
Middle 0.27 (0.07;1.02) 
High 0.77 (0.23;2.62) 
Disclosure 0.77 (0.26;2.31) 
Duration 0.98 (0.96;1.00) 0.98 (0.96;1.00) 
Marriage 0.40 (0.10;1.57) 
Cohabitation 0.60 (0.18;1.94) 
Concurrency 2.35 (0.37;15.03) 
Pregnancy intention 
Discussed, agreed ----- ----- ----- ----- 




Appendix M7: Behavioral characteristics associated with experiences of IPV in the past 12 












	   OR 95% CI OR 95% CI 
Age 	   	   0.99 (0.95;1.04) 
SES 	   	   	   	  
Low ----- ----- ----- ----- 
Middle 	   	   0.67 (0.39;1.17) 
High 	   	   0.70 (0.40;1.23) 
Alcohol/Drugs 6.27 (3.62;10.85) 5.83 (3.32;10.25) 
Distress 2.72 (1.70;4.35) 2.12 (1.27;3.54) 
Depression 2.91 (1.61;5.27) 2.41 (1.27;4.60) 
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Appendix M8: Behavioral characteristics associated with experiences of IPV in the past 12 













	   OR 95% CI OR 95% CI 
Age 	   	   0.98 (0.89;1.08) 
SES 	   	   	   	  
Low ----- ----- ----- ----- 
Middle 	   	   0.33 (0.09;1.28) 
High 	   	   0.80 (0.23;2.75) 
Alcohol/Drugs 1.58 (0.37;6.71) 	   	  
Distress 3.12 (1.05;9.32) 3.12 (1.05;9.32) 
Depression 2.09 (0.54;8.08) 	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Manuscripts  for  Research  articles  submitted  to  BMC  Women's  Health  should  be  divided  into  the  following  sections  (in  this  order): 





Results  and  discussion 
Conclusions 
List  of  abbreviations  used  (if  any) 
Competing  interests 
Authors'  contributions 




Illustrations  and  figures  (if  any) 
Tables  and  captions 
Preparing  additional  files 
The  Accession  Numbers  of  any  nucleic  acid  sequences,  protein  sequences  or  atomic  coordinates  cited  in  the  manuscript  should  be  provided,  in  square  brackets  and 
include  the  corresponding  database  name;;  for  example,  [EMBL:AB026295,  EMBL:AC137000,  DDBJ:AE000812,  GenBank:U49845,  PDB:1BFM,  Swiss--Prot:Q96KQ7, 
PIR:S66116]. 
The  databases  for  which  we  can  provide  direct  links  are:  EMBL  Nucleotide  Sequence  Database  (EMBL),  DNA  Data  Bank  of  Japan  (DDBJ),  GenBank  at  the  NCBI  (GenBank), 
Protein  Data  Bank  (PDB),  Protein  Information  Resource  (PIR)  and  the  Swiss--Prot  Protein  Database  (Swiss--Prot). 
For  reporting  standards  please  see  the  information  in  the  About  section. 
Title  page 
The  title  page  should: 
provide  the  title  of  the  article 
list  the  full  names,  institutional  addresses  and  email  addresses  for  all  authors 
indicate  the  corresponding  author 
Please  note: 
the  title  should  include  the  study  design,  for  example  "A  versus  B  in  the  treatment  of  C:  a  randomized  controlled  trial  X  is  a  risk  factor  for  Y:  a  case  control  study" 
abbreviations  within  the  title  should  be  avoided 
Abstract 
The  Abstract  of  the  manuscript  should  not  exceed  350  words  and  must  be  structured  into  separate  sections:  Background,  the  context  and  purpose  of  the  study;;    
Methods,  how  the  study  was  performed  and  statistical  tests  used;;  Results,  the  main  findings;;  Conclusions,  brief  summary  and  potential  implications.  Please  minimize 
the  use  of  abbreviations  and  do  not  cite  references  in  the  abstract.  Trial  registration,  if  your  research  article  reports  the  results  of  a  controlled  health  care  intervention, 
please  list  your  trial  registry,  along  with  the  unique  identifying  number  (e.g.  Trial  registration:  Current  Controlled  Trials  ISRCTN73824458).  Please  note  that  there  should 
be         no  space  between  the  letters  and  numbers  of  your  trial  registration  number.  We  recommend  manuscripts  that  report  randomized  controlled  trials  follow  the  CONSORT 
extension  for  abstracts. 
Keywords 
Three  to  ten  keywords  representing  the  main  content  of  the  article. 
Background 
The  Background  section  should  be  written  in  a  way  that  is  accessible  to  researchers  without  specialist  knowledge  in  that  area  and  must  clearly  state  --  and,  if  helpful, 
illustrate  --  the  background  to  the  research  and  its  aims.  Reports  of  clinical  research  should,  where  appropriate,  include  a  summary  of  a  search  of  the  literature  to  indicate 
why  this  study  was  necessary  and  what  it  aimed  to  contribute  to  the  field.  The  section  should  end  with  a  brief  statement  of  what  is  being  reported  in  the  article. 
Methods 
The  methods  section  should  include  the  design  of  the  study,  the  setting,  the  type  of  participants  or  materials  involved,  a  clear  description  of  all  interventions  and 
comparisons,  and  the  type  of  analysis  used,  including  a  power  calculation  if  appropriate.  Generic  drug  names  should  generally  be  used.  When  proprietary  brands  are  used 
in  research,  include  the  brand  names  in  parentheses  in  the  Methods  section. 
For  studies  involving  human  participants  a  statement  detailing  ethical  approval  and  consent  should  be  included  in  the  methods  section.  For  further  details  of  the  journal's 
editorial  policies  and  ethical  guidelines  see  'About  this  journal'. 
For  further  details  of  the  journal's  data--release  policy,  see  the  policy  section  in  'About  this  journal'. 
Results  and  discussion 
http://www.biomedcentral.com/bmcwomenshealth/authors/instructions/researcharticle 2/6 
22 
3/6/2015 BMC Women's Health | Instructions for Authors | Research   articles 
The  Results  and  discussion  may  be  combined  into  a  single  section  or  presented  separately.  Results  of  statistical  analysis  should  include,  where  appropriate,  relative  and 
absolute  risks  or  risk  reductions,  and  confidence  intervals.  The  Results  and  discussion  sections  may  also  be  broken  into  subsections  with  short,  informative  headings. 
Conclusions 
This  should  state  clearly  the  main  conclusions  of  the  research  and  give  a  clear  explanation  of  their  importance  and  relevance.  Summary  illustrations  may  be  included. 
List  of  abbreviations 
If  abbreviations  are  used  in  the  text  they  should  be  defined  in  the  text  at  first  use,  and  a  list  of  abbreviations  can  be  provided,  which  should  precede  the  competing 
interests  and  authors'  contributions. 
Competing  interests 
A  competing  interest  exists  when  your  interpretation  of  data  or  presentation  of  information  may  be  influenced  by  your  personal  or  financial  relationship  with  other  people  or 
organizations.  Authors  must  disclose  any  financial  competing  interests;;  they  should  also  reveal  any  non--financial  competing  interests  that  may  cause  them  embarrassment 
were  they  to  become  public  after  the  publication  of  the  manuscript. 
Authors  are  required  to  complete  a  declaration  of  competing  interests.  All  competing  interests  that  are  declared  will  be  listed  at  the  end  of  published  articles.  Where  an 
author  gives  no  competing  interests,  the  listing  will  read  'The  author(s)  declare  that  they  have  no  competing  interests'. 
When  completing  your  declaration,  please  consider  the  following  questions: 
Financial  competing  interests 
In  the  past  three  years  have  you  received  reimbursements,  fees,  funding,  or  salary  from  an  organization  that  may  in  any  way  gain  or  lose  financially  from  the 
publication  of  this  manuscript,  either  now  or  in  the  future?  Is  such  an  organization  financing  this  manuscript  (including  the  article--processing  charge)?  If  so,  please 
specify. 
Do  you  hold  any  stocks  or  shares  in  an  organization  that  may  in  any  way  gain  or  lose  financially  from  the  publication  of  this  manuscript,  either  now  or  in  the  future? 
If  so,  please  specify. 
Do  you  hold  or  are  you  currently  applying  for  any  patents  relating  to  the  content  of  the  manuscript?  Have  you  received  reimbursements,  fees,  funding,  or  salary 
from  an  organization  that  holds  or  has  applied  for  patents  relating  to  the  content  of  the  manuscript?  If  so,  please  specify. 
Do  you  have  any  other  financial  competing  interests?  If  so,  please  specify. 
Non--financial  competing  interests 
Are  there  any  non--financial  competing  interests  (political,  personal,  religious,  ideological,  academic,  intellectual,  commercial  or  any  other)  to  declare  in  relation  to  this 
manuscript?  If  so,  please  specify. 
If  you  are  unsure  as  to  whether  you,  or  one  your  co--authors,  has  a  competing  interest  please  discuss  it  with  the  editorial  office. 
Authors'  contributions 
In  order  to  give  appropriate  credit  to  each  author  of  a  paper,  the  individual  contributions  of  authors  to  the  manuscript  should  be  specified  in  this  section. 
According  to  ICMJE  guidelines,  An  'author'  is  generally  considered  to  be  someone  who  has  made  substantive  intellectual  contributions  to  a  published  study.  To  qualify  as  an 
author  one  should  1)  have  made  substantial  contributions  to  conception  and  design,  or  acquisition  of  data,  or  analysis  and  interpretation  of  data;;  2)  have  been  involved  in 
drafting  the  manuscript  or  revising  it  critically  for  important  intellectual  content;;  3)  have  given  final  approval  of  the  version  to  be  published;;  and  4)  agree  to  be  accountable 
for  all  aspects  of  the  work  in  ensuring  that  questions  related  to  the  accuracy  or  integrity  of  any  part  of  the  work  are  appropriately  investigated  and  resolved.  Each  author 
should  have  participated  sufficiently  in  the  work  to  take  public  responsibility  for  appropriate  portions  of  the  content.  Acquisition  of  funding,  collection  of  data,  or  general 
supervision  of  the  research  group,  alone,  does  not  justify  authorship. 
We  suggest  the  following  kind  of  format  (please  use  initials  to  refer  to  each  author's  contribution):  AB  carried  out  the  molecular  genetic  studies,  participated  in  the 
sequence  alignment  and  drafted  the  manuscript.  JY  carried  out  the  immunoassays.  MT  participated  in  the  sequence  alignment.  ES  participated  in  the  design  of  the  study 
and  performed  the  statistical  analysis.  FG  conceived  of  the  study,  and  participated  in  its  design  and  coordination  and  helped  to  draft  the  manuscript.  All  authors  read  and 
approved  the  final  manuscript. 
All  contributors  who  do  not  meet  the  criteria  for  authorship  should  be  listed  in  an  acknowledgements  section.  Examples  of  those  who  might  be  acknowledged  include  a 
person  who  provided  purely  technical  help,  writing  assistance,  or  a  department  chair  who  provided  only  general  support. 
Authors'  information 
You  may  choose  to  use  this  section  to  include  any  relevant  information  about  the  author(s)  that  may  aid  the  reader's  interpretation  of  the  article,  and  understand  the 
standpoint  of  the  author(s).  This  may  include  details  about  the  authors'  qualifications,  current  positions  they  hold  at  institutions  or  societies,  or  any  other  relevant 
background  information.  Please  refer  to  authors  using  their  initials.  Note  this  section  should  not  be  used  to  describe  any  competing  interests. 
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Please  acknowledge  anyone  who  contributed  towards  the  article  by  making  substantial  contributions  to  conception,  design,  acquisition  of  data,  or  analysis  and 
interpretation  of  data,  or  who  was  involved  in  drafting  the  manuscript  or  revising  it  critically  for  important  intellectual  content,  but  who  does  not  meet  the  criteria  for 
authorship.  Please  also  include  the  source(s)  of  funding  for  each  author,  and  for  the  manuscript  preparation.  Authors  must  describe  the  role  of  the  funding  body,  if  any,  in 
design,  in  the  collection,  analysis,  and  interpretation  of  data;;  in  the  writing  of  the  manuscript;;  and  in  the  decision  to  submit  the  manuscript  for  publication.  Please  also 
acknowledge  anyone  who  contributed  materials  essential  for  the  study.  If  a  language  editor  has  made  significant  revision  of  the  manuscript,  we  recommend  that  you 
acknowledge  the  editor  by  name,  where  possible. 
The  role  of  a  scientific  (medical)  writer  must  be  included  in  the  acknowledgements  section,  including  their  source(s)  of  funding.  We  suggest  wording  such  as  'We  thank  Jane 
Doe  who  provided  medical  writing  services  on  behalf  of  XYZ  Pharmaceuticals  Ltd.' 
Authors  should  obtain  permission  to  acknowledge  from  all  those  mentioned  in  the  Acknowledgements  section. 
Endnotes 
Endnotes  should  be  designated  within  the  text  using  a  superscript  lowercase  letter  and  all  notes  (along  with  their  corresponding  letter)  should  be  included  in  the  Endnotes 
section.  Please  format  this  section  in  a  paragraph  rather  than  a  list. 
References 
All  references,  including  URLs,  must  be  numbered  consecutively,  in  square  brackets,  in  the  order  in  which  they  are  cited  in  the  text,  followed  by  any  in  tables  or  legends. 
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Each  reference  must  have  an  individual  reference  number.  Please  avoid  excessive  referencing.  If  automatic  numbering  systems  are  used,  the  reference  numbers  must  be 
finalized  and  the  bibliography  must  be  fully  formatted  before  submission. 
 
Only  articles,  clinical  trial  registration  records  and  abstracts  that  have  been  published  or  are  in  press,  or  are  available  through  public  e--print/preprint  servers,  may  be  cited;; 
unpublished  abstracts,  unpublished  data  and  personal  communications  should  not  be  included  in  the  reference  list,  but  may  be  included  in  the  text  and  referred  to  as 
"unpublished  observations"  or  "personal  communications"  giving  the  names  of  the  involved  researchers.  Obtaining  permission  to  quote  personal  communications  and 
unpublished  data  from  the  cited  colleagues  is  the  responsibility  of  the  author.  Footnotes  are  not  allowed,  but  endnotes  are  permitted.  Journal  abbreviations  follow  Index 
Medicus/MEDLINE.  Citations  in  the  reference  list  should  include  all  named  authors,  up  to  the  first  six  before  adding  'et  al.'.. 
 
Any  in  press  articles  cited  within  the  references  and  necessary  for  the  reviewers'  assessment  of  the  manuscript  should  be  made  available  if  requested  by  the  editorial  office. 
An  Endnote  style  file  is  available. 
Examples  of  the  BMC  Women's  Health  reference  style  are  shown  below.  Please  ensure  that  the  reference  style  is  followed  precisely;;  if  the  references  are  not  in  the  correct 
style  they  may  have  to  be  retyped  and  carefully  proofread. 
 
All  web  links  and  URLs,  including  links  to  the  authors'  own  websites,  should  be  given  a  reference  number  and  included  in  the  reference  list  rather  than  within  the  text  of  the 
manuscript.  They  should  be  provided  in  full,  including  both  the  title  of  the  site  and  the  URL,  as  well  as  the  date  the  site  was  accessed,  in  the  following  format:  The  Mouse 
Tumor  Biology  Database.  http://tumor.informatics.jax.org/mtbwi/index.do.  Accessed  20  May  2013.  If  an  author  or  group  of  authors  can  clearly  be  associated  with  a  web 
link,  such  as  for  weblogs,  then  they  should  be  included  in  the  reference. 
 
Examples  of  the  BMC  Women's  Health  reference  style 
 
Article  within  a  journal 
Smith  JJ.  The  world  of  science.  Am  J  Sci.  1999;;36:234--5. 
 
Article  within  a  journal  (no  page  numbers) 
Rohrmann  S,  Overvad  K,  Bueno--de--Mesquita  HB,  Jakobsen  MU,  Egeberg  R,  Tjønneland  A,  et  al.  Meat  consumption  and  mortality  --  results  from  the  European  Prospective 
Investigation  into  Cancer  and  Nutrition.  BMC  Medicine.  2013;;11:63. 
 
Article  within  a  journal  by  DOI 
Slifka  MK,  Whitton  JL.  Clinical  implications  of  dysregulated  cytokine  production.  Dig  J  Mol  Med.  2000;;  doi:10.1007/s801090000086. 
 
Article  within  a  journal  supplement 
Frumin  AM,  Nussbaum  J,  Esposito  M.  Functional  asplenia:  demonstration  of  splenic  activity  by  bone  marrow  scan.  Blood  1979;;59  Suppl  1:26--32. 
 
Book  chapter,  or  an  article  within  a  book 
Wyllie  AH,  Kerr  JFR,  Currie  AR.  Cell  death:  the  significance  of  apoptosis.  In:  Bourne  GH,  Danielli  JF,  Jeon  KW,  editors.  International  review  of  cytology.  London:  Academic;; 
1980.  p.  251--306. 
 
OnlineFirst  chapter  in  a  series  (without  a  volume  designation  but  with  a  DOI) 
Saito  Y,  Hyuga  H.  Rate  equation  approaches  to  amplification  of  enantiomeric  excess  and  chiral  symmetry  breaking.  Top  Curr  Chem.  2007.  doi:10.1007/128_2006_108. 
 
Complete  book,  authored 
Blenkinsopp  A,  Paxton  P.  Symptoms  in  the  pharmacy:  a  guide  to  the  management  of  common  illness.  3rd  ed.  Oxford:  Blackwell  Science;;  1998. 
 
Online  document 
Doe  J.  Title  of  subordinate  document.  In:  The  dictionary  of  substances  and  their  effects.  Royal  Society  of  Chemistry.  1999.  http://www.rsc.org/dose/title  of  subordinate 
document.  Accessed  15  Jan  1999. 
 
Online  database 
Healthwise  Knowledgebase.  US  Pharmacopeia,  Rockville.  1998.  http://www.healthwise.org.  Accessed  21  Sept  1998. 
 
Supplementary  material/private  homepage 
Doe  J.  Title  of  supplementary  material.  2000.  http://www.privatehomepage.com.  Accessed  22  Feb  2000. 
 
University  site 
Doe,  J:  Title  of  preprint.  http://www.uni--heidelberg.de/mydata.html  (1999).  Accessed  25  Dec  1999. 
 
FTP  site 
Doe,  J:  Trivial  HTTP,  RFC2169.  ftp://ftp.isi.edu/in--notes/rfc2169.txt  (1999).  Accessed  12  Nov  1999. 
 
Organization  site 
ISSN  International  Centre:  The  ISSN  register.  http://www.issn.org  (2006).  Accessed  20  Feb  2007. 
 
 
Preparing  illustrations  and  figures 
 
Illustrations  should  be  provided  as  separate  files,  not  embedded  in  the  text  file.  Each  figure  should  include  a  single  illustration  and  should  fit  on  a  single  page  in  portrait 
format.  If  a  figure  consists  of  separate  parts,  it  is  important  that  a  single  composite  illustration  file  be  submitted  which  contains  all  parts  of  the  figure.  There  is  no  charge 
for  the  use  of  color  figures. 
 
Please  read  our  figure  preparation  guidelines  for  detailed  instructions  on  maximising  the  quality  of  your  figures. 
 
Formats 
The  following  file  formats  can  be  accepted: 
 
 
PDF  (preferred  format  for  diagrams) 
DOCX/DOC  (single  page  only) 
PPTX/PPT  (single  slide  only) 
EPS 
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BMP 
Figure  legends 
The  legends  should  be  included  in  the  main  manuscript  text  file  at  the  end  of  the  document,  rather  than  being  a  part  of  the  figure  file.  For  each  figure,  the  following 
information  should  be  provided:  Figure  number  (in  sequence,  using  Arabic  numerals  --  i.e.  Figure  1,  2,  3  etc);;  short  title  of  figure  (maximum  15  words);;  detailed  legend,  up 
to  300  words. 
Please  note  that  it  is  the  responsibility  of  the  author(s)  to  obtain  permission  from  the  copyright  holder  to  reproduce  figures  or  tables  that  have  previously 
been  published  elsewhere. 
Preparing  tables 
Each  table  should  be  numbered  and  cited  in  sequence  using  Arabic  numerals  (i.e.  Table  1,  2,  3  etc.).  Tables  should  also  have  a  title  (above  the  table)  that  summarizes  the 
whole  table;;  it  should  be  no  longer  than  15  words.  Detailed  legends  may  then  follow,  but  they  should  be  concise.  Tables  should  always  be  cited  in  text  in  consecutive 
numerical  order. 
Smaller  tables  considered  to  be  integral  to  the  manuscript  can  be  pasted  into  the  end  of  the  document  text  file,  in  A4  portrait  or  landscape  format.  These  will  be  typeset 
and  displayed  in  the  final  published  form  of  the  article.  Such  tables  should  be  formatted  using  the  'Table  object'  in  a  word  processing  program  to  ensure  that  columns  of 
data  are  kept  aligned  when  the  file  is  sent  electronically  for  review;;  this  will  not  always  be  the  case  if  columns  are  generated  by  simply  using  tabs  to  separate  text. 
Columns  and  rows  of  data  should  be  made  visibly  distinct  by  ensuring  that  the  borders  of  each  cell  display  as  black  lines.  Commas  should  not  be  used  to  indicate  numerical 
values.  Color  and  shading  may  not  be  used;;  parts  of  the  table  can  be  highlighted  using  symbols  or  bold  text,  the  meaning  of  which  should  be  explained  in  a  table  legend. 
Tables  should  not  be  embedded  as  figures  or  spreadsheet  files. 
Larger  datasets  or  tables  too  wide  for  a  portrait  page  can  be  uploaded  separately  as  additional  files.  Additional  files  will  not  be  displayed  in  the  final,  laid--out  PDF  of  the 
article,  but  a  link  will  be  provided  to  the  files  as  supplied  by  the  author. 
Tabular  data  provided  as  additional  files  can  be  uploaded  as  an  Excel  spreadsheet  (.xls  )  or  comma  separated  values  (.csv).  As  with  all  files,  please  use  the  standard  file 
extensions. 
Preparing  additional  files 
Although  BMC  Women's  Health  does  not  restrict  the  length  and  quantity  of  data  included  in  an  article,  we  encourage  authors  to  provide  datasets,  tables,  movies,  or  other 
information  as  additional  files. 
Please  note:  All  Additional  files  will  be  published  along  with  the  article.  Do  not  include  files  such  as  patient  consent  forms,  certificates  of  language  editing,  or  revised 
versions  of  the  main  manuscript  document  with  tracked  changes.  Such  files  should  be  sent  by  email  to  editorial@biomedcentral.com,  quoting  the  Manuscript  ID  number. 
Results  that  would  otherwise  be  indicated  as  "data  not  shown"  can  and  should  be  included  as  additional  files.  Since  many  weblinks  and  URLs  rapidly  become  broken,  BMC 
Women's  Health  requires  that  supporting  data  are  included  as  additional  files,  or  deposited  in  a  recognized  repository.  Please  do  not  link  to  data  on  a 
personal/departmental  website.  The  maximum  file  size  for  additional  files  is  20  MB  each,  and  files  will  be  virus--scanned  on  submission. 
Additional  files  can  be  in  any  format,  and  will  be  downloadable  from  the  final  published  article  as  supplied  by  the  author.  We  recommend  CSV  rather  than  PDF  for  tabular 
data. 
Certain  supported  files  formats  are  recognized  and  can  be  displayed  to  the  user  in  the  browser.  These  include  most  movie  formats  (for  users  with  the  Quicktime  plugin), 
mini--websites  prepared  according  to  our  guidelines,  chemical  structure  files  (MOL,  PDB),  geographic  data  files  (KML). 
If  additional  material  is  provided,  please  list  the  following  information  in  a  separate  section  of  the  manuscript  text: 
File  name  (e.g.  Additional  file  1) 
File  format  including  the  correct  file  extension  for  example  .pdf,  .xls,  .txt,  .pptx  (including  name  and  a  URL  of  an  appropriate  viewer  if  format  is  unusual) 
Title  of  data 
Description  of  data 
Additional  files  should  be  named  "Additional  file  1"  and  so  on  and  should  be  referenced  explicitly  by  file  name  within  the  body  of  the  article,  e.g.  'An  additional  movie  file 
shows  this  in  more  detail  [see  Additional  file  1]'. 
Additional  file  formats 
Ideally,  file  formats  for  additional  files  should  not  be  platform--specific,  and  should  be  viewable  using  free  or  widely  available  tools.  The  following  are  examples  of  suitable 
formats. 
Additional  documentation 
PDF  (Adode  Acrobat) 
Animations 
SWF  (Shockwave  Flash) 
Movies 
MP4  (MPEG  4) 
MOV  (Quicktime) 
Tabular  data 
XLS,  XLSX  (Excel  Spreadsheet) 
CSV  (Comma  separated  values) 
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Small  self--contained  websites  can  be  submitted  as  additional  files,  in  such  a  way  that  they  will  be  browsable  from  within  the  full  text  HTML  version  of  the  article.  In  order  to 
do  this,  please  follow  these  instructions: 
Create  a  folder  containing  a  starting  file  called  index.html  (or  index.htm)  in  the  root. 
Put  all  files  necessary  for  viewing  the  mini--website  within  the  folder,  or  sub--folders. 
Ensure  that  all  links  are  relative  (ie  "images/picture.jpg"  rather  than  "/images/picture.jpg"  or  "http://yourdomain.net/images/picture.jpg"  or  "C:\Documents  and 
Settings\username\My  Documents\mini--website\images\picture.jpg")  and  no  link  is  longer  than  255  characters. 
Access  the  index.html  file  and  browse  around  the  mini--website,  to  ensure  that  the  most  commonly  used  browsers  (Internet  Explorer  and  Firefox)  are  able  to  view  all 
parts  of  the  mini--website  without  problems,  it  is  ideal  to  check  this  on  a  different  machine. 
Compress  the  folder  into  a  ZIP,  check  the  file  size  is  under  20  MB,  ensure  that  index.html  is  in  the  root  of  the  ZIP,  and  that  the  file  has  .zip  extension,  then  submit 
as  an  additional  file  with  your  article. 
Style  and  language 
General 
Currently,  BMC  Women's  Health  can  only  accept  manuscripts  written  in  English.  Spelling  should  be  US  English  or  British  English,  but  not  a  mixture. 
There  is  no  explicit  limit  on  the  length  of  articles  submitted,  but  authors  are  encouraged  to  be  concise. 
BMC  Women's  Health  will  not  edit  submitted  manuscripts  for  style  or  language;;  reviewers  may  advise  rejection  of  a  manuscript  if  it  is  compromised  by  grammatical  errors. 
Authors  are  advised  to  write  clearly  and  simply,  and  to  have  their  article  checked  by  colleagues  before  submission.  In--house  copyediting  will  be  minimal.  Non--native 
speakers  of  English  may  choose  to  make  use  of  a  copyediting  service. 
Language  editing 
For  authors  who  wish  to  have  the  language  in  their  manuscript  edited  by  a  native--English  speaker  with  scientific  expertise,  BioMed  Central  recommends  Edanz.  BioMed 
Central  has  arranged  a  10%  discount  to  the  fee  charged  to  BioMed  Central  authors  by  Edanz.  Use  of  an  editing  service  is  neither  a  requirement  nor  a  guarantee  of 
acceptance  for  publication.  Please  contact  Edanz  directly  to  make  arrangements  for  editing,  and  for  pricing  and  payment  details. 
Help  and  advice  on  scientific  writing 
The  abstract  is  one  of  the  most  important  parts  of  a  manuscript.  For  guidance,  please  visit  our  page  on  Writing  titles  and  abstracts  for  scientific  articles. 
Tim  Albert  has  produced  for  BioMed  Central  a  list  of  tips  for  writing  a  scientific  manuscript.  American  Scientist  also  provides  a  list  of  resources  for  science  writing.  For  more 
detailed  guidance  on  preparing  a  manuscript  and  writing  in  English,  please  visit  the  BioMed  Central  author  academy. 
Abbreviations 
Abbreviations  should  be  used  as  sparingly  as  possible.  They  should  be  defined  when  first  used  and  a  list  of  abbreviations  can  be  provided  following  the  main  manuscript 
text. 
Typography 
Please  use  double  line  spacing. 
Type  the  text  unjustified,  without  hyphenating  words  at  line  breaks. 
Use  hard  returns  only  to  end  headings  and  paragraphs,  not  to  rearrange  lines. 
Capitalize  only  the  first  word,  and  proper  nouns,  in  the  title. 
All  lines  and  pages  should  be  numbered.  Authors  are  asked  to  ensure  that  line  numbering  is  included  in  the  main  text  file  of  their  manuscript  at  the  time  of 
submission  to  facilitate  peer--review.  Once  a  manuscript  has  been  accepted,  line  numbering  should  be  removed  from  the  manuscript  before  publication.  For  authors 
submitting  their  manuscript  in  Microsoft  Word  please  do  not  insert  page  breaks  in  your  manuscript  to  ensure  page  numbering  is  consistent  between  your  text  file  and 
the              PDF  generated  from  your  submission  and  used  in  the  review  process. 
Use  the  BMC  Women's  Health  reference  format. 
Footnotes  are  not  allowed,  but  endnotes  are  permitted. 
Please  do  not  format  the  text  in  multiple  columns. 
Greek  and  other  special  characters  may  be  included.  If  you  are  unable  to  reproduce  a  particular  special  character,  please  type  out  the  name  of  the  symbol  in  full. 
Please  ensure  that  all  special  characters  used  are  embedded  in  the  text,  otherwise  they  will  be  lost  during  conversion  to  PDF. 
Units 
SI  units  should  be  used  throughout  (liter  and  molar  are  permitted,  however). 
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